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Microbiology

Nonspecific Inhibition of Encephalomyocarditis Virus
Replication by Immune Interferon Released from Unstimu
lated Cells of Mice Sensitized with Nonviable Mycobac
terium tuberculosis (102 pp.)
Director: Donald L. Lodmell
Inhibition of encephalomyocarditis virus (EMCV)
replication was demonstrated in mouse embryo fibroblasts
(MEF) monolayers by incubating peritoneal cells (PC)
from mice sensitized intraperitoneally (i.p.) or intraveneously (i.v.) 2-10 weeks previously with 50-500 ug
of nonviable Mycobacterium tuberculosis, strain Jamaica,
suspended in an oil-in-saline emulsion. PC from mycobacteria-sensitized mice at a PC-to-MEF ratio of 20
inhibited viral replication by >. 1-2 log^o as compared
to PC from normal mice when incubated on MEF monolayers
infected 2-8 h previously with EMCV. Inhibition of
EMCV replication was first detected 12 h post-infection
and was not due to depletion of culture nutrients,
changes in pH, nor temperature dependence. In addition,
EMCV was prevented from spreading to uninfected mono
layer cells, but viral inhibition was not due to cyto
toxicity of MEF by PC. Supernatant fluids prepared
from PC cultures of mycobacteria-sensitized mice in
hibited viral replication. The antiviral activity in
supernatant fluids elicited without mycobacterial
antigen stimulation was labile to acid, heat and trypsin,
and was active in mouse cells against several RNA or
DNA viruses. Furthermore, the antiviral activity of
supernatant fluids was neutralized by rabbit anti-type
II mouse interferon, but not anti-type I mouse interferon.
Thus, an immune type II mouse interferon released from
unstimulated PC of mycobacteria-sensitized mice appears
to be responsible for the inhibition of EMCV replication.
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INTRODUCTION

The importance of cell-mediated immunity (CMI) in viral
infections is well documented (13»38,64).

Individuals with

agammaglobulinemia recover normally from most viral infec
tions, yet those lacking in CMI do not (64).

The mechanisms

of protection in Civil are varied, but include two major
types: specific responses elicited by antigens similiar to
the infectious agent that ultimately provide protection
against only that agent (7.20,22), and nonspecific responses
elicited by agents which induce a state of resistance
against a variety of phylogenetically diverse organisms (59).
Several facultative intracellular bacterial species known
to induce nonspecific CMI ard ivlycobacteria, especially
Bacille Calmette-Guerin (BCG), Corynebacteria, Listeria,
Brucella, and Salmonella, although chemical compounds such
as pyran, polyinosinic acid-polycytidylic acid (poly (I)poly (G)) and thioglycollate also can elicit nonspecific
CMI (30,42).

The nonspecific CMI induced by facultative

intracellular parasites appear to share several character
istics: there is an association with delayed hypersensitiv
ity, the acquired resistance cannot be passively transferred
with serum, and there is an increase in host macrophage
activity (43).

In addition, immunological resistance in

duced by facultative intracellular parasites can protect
the host against neoplasms and a variety of organisms
including bacteria, protozoa, and viruses (36,59).
1

2
Because immunological resistance can be attained against
unrelated organisms, it has been suggested that common
mechanisms of immunity underlie all intracellular infectrions (59)•
Many investigations have been conducted on the non
specific phase of CMI to determine its role in the immune
response.

One of the earliest studies was done by Mackaness

et al. who used BCG to induce resistance to Listeria mono
cytogenes and Salmonella typhimurium (6, 43).

Six days

after intravenous (i.v.) injection with live BCG, suseptible
mice were highly resistant to i.v. challenge with virulent
L. monocytogenes (6).

Resistance was determined by the

increased rate of clearance of L. monocytogenes from the
blood, decreased numbers of challenge bacteria present
in the liver and spleen and by the increased survival
of mice.

In another study, Sulitzeanu induced resistance

"k° Brucella abortus following an intraperitoneal (i.p.)
or i.v. challenge by the L.p. injection 7-14 days previous
ly with either live or dead BCG (68).

As in the previous

study, resistance was associated with decreased numbers
of the challenge bacteria in the liver and spleen.
The nonspecific enhancement of resistance by BCG is
not limited to bacteria.

Civil et al. demonstrated enhanced

resistance to Schistosoma mansoni, a multicellular helminth
parasite, that was dependent on the dose, route, and time
of administration of BCG, as well as the strain of mouse
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used (10).

Nonspecific Civil also was demonstrated in vivo

and in vitro by Ruskin ejt al. with mice chronically infected
with Toxoplasma (59).

When animals were challenged with a

lethal dose of Listeria, mortality decreased from 100 to
and this resistance could not be passively transferred with
sera to normal mice.

Furthermore, monolayers of peritoneal

cells (PC) removed from normal mice were destroyed when
challenged with Listeria, whereas PC monolayers from
Toxoplasma or Besnoitia-infected mice persisted.
More recently, work with nonspecific Civil has been ex
panded to include resistance to viral infections and
tumors.

In a study done by Starr et al., i.p. or intra

dermal (i.d.) administration of live BCG to newborn mice
6 days prior to challenge with herpes simplex virus (HSV),
increased the survival time of the animals (66).

Kirchner

et al. also were able to induce resistance to HSV by the
i.p. or i.v. injection of killed Corynebacterium parvum or
Bordetella pertussis (33).

In some instances, nonspecific

resistance to infections has been demonstrated with cell
walls or other fractions of the eliciting organisms (8, 32).
One example of such a

study was done by Kern e_t al. in

which Bru-Pel, a cell wall preparation of Brucella abortus,
injected i.p. induced significant protection in mice
challenged i.p.with HSV type 2 (32); the protective effect
of Bru-Pel was not detected if virus was given intranasally.
Other investigators have studied antitumor as well as
antiviral effects in nonspecifically mediated CMI (8, 11, 36).

4
In a study by Lamensans e_t al., it was determined that an
i.p. injection of BCG 14 days prior to i.p. implantation
of Leukemia-L 1210 cells significantly increased the mean
survival time (MST) of mice (36).

The same prophylactic

treatment also increased the MST of mice challenged with
Columbia SK virus.

Studies conducted by Clark et al.

noted similarities

in resistance to babesiosis and tumor

regression elicited by BCG infection (11).

These similar

ities included enhanced protection following an i.v. rather
than subcutaneous (s.c.) injection of BCG, protection in
thymectomized or splenectomized animals (as long as the
spleen was removed prior to BCG administration) and mechan
isms of protection that were resistant to radiation and
cyclophosphamide, but not to cortisone.
A number of immunological mechanisms have been associ
ated with nonspecific enhancement of resistance (2, 35» 42).
Many early studies noted an increased activity of the
reticuloendothial system (Kj23) and it was postulated that
activated macrophages were effective against many organisms,
including those that were used to induce their elevated
state of activity (42, 43).

Activated macrophages were

first described by Mackaness who noted th.-it they had an
increased metabolism, enhanced phagocytic capability, high
microbicidal activity and a distinctive morphology.(42, 55)»
In addition, activated macrophages recently have been shown
to possess a marked tumoricidal effect as well as an ability
to inhibit viral replication (1, 3°).

Furthermore Schleupner
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et al.,utilizing the technique of chemiluminescence (GL),
demonstrated that viral infections induce activated macro
phages; PC from vaccinia virus (VV) or cytomegalovirus (CMV)infected animals emitted increased amounts of CL during
phagocytosis of zymosan particles or yeasts as compared
to PC from uninfected animals (61).

CL is a technique

which measures the amount of light emitted by phagocytic
cells; the source of light is thought to involve interac
tions of the ingested particles and oxidizing agents of
the cells (H^Og* 02~. etc.) (9).

Activated macrophages,

because of their increased metabolism, have more oxidizing
agents and thus emit increased amounts of CL (9» 61).
Because more recent studies have indicated that macrophage
activation is a varied phenomena, new criteria based on biochemi
cal activity as well as differences in antitumor and anti
viral activities (51) have been established to precisely
define the mechanisms of activation (31).

It has been

established that 1) activated macrophages are derived from
animals infected with BCG, Listeria, or other facultative:
intracellular parasites, 2) stimulated or elicited macro
phages are from animals injected with peptone, thioglycollate
or chemical substances and 3) specifically conditioned
macrophages are those that have been exposed Ln vitro to
products of stimulated lymphocytes.(31)•
Many studies have been undertaken to characterize the
mechanism of macrophage activation, and in several instances,
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there appears to be an interaction between two or more
immunological cell types (25, 35)• Hadden has determined
that sensitized lymphocytes, when restimulated with specific,
antigen (Ag), produce macrophage mitogenic factor (MMF)
which causes macrophages to proliferate in culture (25).
Prostaglandin has been postulated to act as a negative
feedback regulator

of MMF function, although it was

indicated that interferon or migration inhibitory factor
(MIF) also could act in this capacity (25).
The antiviral mechanisms of activated macrophages have
been more thoroughly characterized.

Increased phagocytosis

of the virions or virus-infected cells (cytotoxicity) can
occur, as well as inhibition of viral replication through
the mechanism of compartmentalization (52, 55» 56, 64).
Early investigations by Muyembe et al. concluded that mice
injected i.p. v/ith Brucella abortus were resistant to Mengo
virus infection by the same route because virus in the peri
toneum was trapped by macrophages and thus did not reach
the circulation (52).

A similiar conclusion was reached

by Spencer et al. who demonstrated that local (nasal)
immunization with BCG elicited significantly better local
CMI than did parenterally immunized animals, in
contrast, parenterally immunized animals demonstrated better
systemic immunity (64, 65).

Mims and Gould described a

compartmentalization-type phenomena in vitro in which a CMV
infection was contained by broth-stimulated macrophages and
thereby prevented from spreading to suseptible underlying

7
mouse embryo fibroblasts (MEF) monolayers (49).

In this

system, differences were noted between stimulated and normal
macrophages by their ability to contain, control and inac
tivate virus after phagocytosis,

macrophages cytotoxic

for virus-infected cells have been shown by Kaplan who
demonstrated that pyran-stimulated macrophages were effective
in halting tumor growth (30)» and by Probert who showed that
unstimulated calf alveolar macrophages were cytotoxic and
responsible for inhibition of parainfluenza-3 (PI-3) viral
replication in calf

kidney cells (54).

In addition, Rodda

et al. studied the inhibition of Semliki Forest Virus (SFV)
replication in Vero cells by PC or spleen cells from normal
mice or mice which had been infected with SFV (56).

It was

determined that cytotoxic macrophages were present one day
after viral injection, peaked on days 2 and 3 and disappeared
within a week.

Specific immune responses in the form of

sensitized-T cells and cytotoxic Ab then appeared (56).
Thus, activated macrophages were functioning as early reg
ulatory cells co-operating with other components of the
immune system.

This early regulation also was demonstrated

by Kurland ejt al. who detected the release of a soluble
mediator from thioglycollate-stimulated macrophages which
caused B cell proliferation iri vitro (35).
Activated macrophages, as well as T and B lymphocytes,
have been demonstrated to release a number of immunological
mediators, the most well studied of which is interferon
(35, 44).

This nonspecific antiviral mediator was discovered
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in 1957 "by Isaacs and Lindenmann (3» 18), and on a molar
basis it is one of the most active protein molecules
known (18).

There are two types of mouse interferon which

are well characterized, although it is possible that others
exist.

Type I interferon, induced by nonspecific stimuli such

as poly (I)-poly (C) or viruses, is heat labile and acid stable,
whereas type II, immune or T interferon which is heat stable
and acid labile is produced by sensitized cells in response
to a specific Ag (18).

Physically, interferon molecules

which are quite heterogeneous also differ in their biological
properties depending on their cellular source and mode of
induction.

Type I interferon generally is associated with

macrophages and nonspecific stimuli, whereas lymphocytes
produce immune type II interferon after antigenic stimulation
of sensitized cells (44).

All interferons are nondialyzable,

sensitive to trypsin, and are usually species, but not viral
specific (3)«

Their molecular weights have been reported

to range from 18,000 to 100,000 daltons which reflect the
heterogenicity of the molecules involved (5).
Interferons have been associated with nonspecific viral
inhibition in many studies including the one conducted by
Kern e_t al. (32).

In this system, an ether extract of

Brucella abortus (Bru-Pel) when injected i.p. 6-12 h before
encephalomyocarditis virus (EMCV) or HSV, induced high levels
of type I interferon.

In addition, Bru-Pel when injected

7-14 days before virus challenge was shown to activate the
RES which also protected mice.

Thus, interferon was postulated
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to play an early regulatory role in viral infections.
Similiar results have been reported by Virelizier ejt al.
who showed that type I interferon was important in the ini
tial resistance to mouse hepatitis virus type 3. "but it was
not the sole immunological response associated with pro
tection of infected animals (70).

The interferon was

capable, however, of containing the viral infection until
other parameters of the immune system, such as antiviral
activated macrophages could respond.

In other studies,

Suntharasamai and Rytel (69) demonstrated that an i.p.
injection of Eperythrozoon coccoides, a blood parasite,
induced high levels of interferon.

The production of inter

feron was biphasic in that it peaked on day 1, dropped in
titer, and then peaked again on day 4.

Its effect on para

sitemia was transient in that there was an initial delay in
replication of the blood parasite followed by an enhancement
of replication.

In contrast, E. coccoides has been shown

to protect mice against SFV challenge and this protection
was thought to be mediated through type I interferon.

Hirt

et al. studied another system in which spleen cells from
mice injected with C. parvum were found to produce high
levels of immune interferon with and without stimulation
of sensitized cells by the addition of corynebacteria to the
culture system (26).

Immune interferon was identified as

the mediator with physical characterization studies and by
its inhibition of viral replication in pretreated target
cells.

The presence of interferon also was detected in an
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in vitro study by Lodmell and Notkins with HSV-infected
primary rabbit kidney (PRK) cells (38).

Leukocytes removed

from rabbits previously stimulated with HSV or complete
Freund's adjuvant (CFA) inhibited viral replication in
vitro after incubation of the effector cells with specific
Ag.

A mediator present in supernatant fluids harvested

from the stimulated leukocytes also inhibited viral repli
cation, and based on biological characteristics and behavior
of the mediator, it was identified as interferon.
conducted an in vivo study in which

Gresser

anti-mouse type I

interferon was administered to mice prior to Eiv'iCV challenge
(24).

The mice which had been given the antisera plus

virus died of an overwhelming systemic disease in 3 days
rather than at 5 days of a central nervous system (CMS) dis
order, which occurs in mice that had received only the virus
inoculum (24).

It was concluded that interferon was impor

tant in limiting virus replication during the course of
disease by its regulation of the number of virions which
enter the circulation and target organs (1, 24).
Interferons not only act as antiviral mediators, but
they also interact with the immune system and are known to
cause changes in CMI responses (13)•

Type I interferon

prolongs skin graft survival across Hr-2 barriers, abolishes
delayed-type hypersensitivity (DTH) reactions, decreases
development of bone marrow derived cells and causes changes
in lymphocyte cell surfaces (13)•

In addition, Manejias

conducted a study in v/hich he postulated a direct correlation
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between the production of type I interferon and an increased
ability of PC from mice infected with Newcastle Disease
Virus (NDV) to phagocytize Ab-coated erythrocytes (45).
The role of type II interferon is less clear but it is
thought to control and to regulate immune functions during
viral infections (13)•
Biochemically, the antiviral mechanism of interferon
activity has been analysed by a number of investigators.
During the early stages of virus infection, some event,
probably the presence of foreign virion nucleic acid,
derepresses a cellular gene which results in interferon
production (3)»

The interferon does not inhibit viral

replication but it is secreted into the extracellular fluid
where it reacts with membranes of surrounding cells to derepress a second gene within the cells.

This derepression

results in the production of intracellular antiviral proteins
which inhibit synthesis of essential viral proteins or
mRNA (3, 46).

Thus, this mechanism explains the nonspecific,

nature of interferon molecules; a broad range of viruses
can stimulate interferons that are specific for the animal
cell type in which they are induced (3).
Antiviral mediators that cannot be classified as
known interferons have been detected (34, 47, 58)*

Kirchner

showed that spleen cells from C. parvum-sensitized mice
produced a factor which inhibited HSV replication in MSF
monolayers, yet he was not able to conclusively identify
this substance as any of the known interferons (34).
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A similiar mediator was described by Rouse et al. who de
tected an antiviral substance in supernatant fluids of
bovine polymorphonuclear (PMW) leukocytes cultures after
exposure to H3V (5^).

This substance was shown to be active

in heterologous cell lines in addition to being intermediate
in its acid stability.

Using these criteria, it was identi

fied as something other than a known bovine interferon.
Antiviral activity also was detected in human and bovine
milk by Matthews jet al. and its behavior was unlike known
interferon preparations (47).

In contrast to interferon,

preincubation of monolayer cells with the milk did not inhi
bit viral replication; the milk had to be added to the mono
layers concurrently with the virus.

From these results,

it was postulated that the antiviral substance interferred
with the attachment or penetration of the virus which is
unlike the known antiviral mechanisms of classical inter
feron (3. 46, 47).
As mentioned previously, interferon not only inhibits
viral replication, but has a number of effects on other
immunological parameters.

For example, Djeu et al. stated

that type I interferon augmented natural killer (NK) cell
activity against tumor cells (14, 15)» and Santoli ejt al.
reached the same conclusion in their study of measles-infects
ed human fibroblasts (60).

Recently, NK cells have been

described as lymphocytes which lack T or B cell markers,
are sensitive to trypsin and are innately cytotoxic (2, 60).
This cytotoxicity can nonspecifically halt viral replication
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by destroying target cells that are necessary for viral
replication.

NK cells are not the only cells which are

cytotoxic; activated macrophages, killer (K) cells, T lymph
ocytes and their soluble lymphokines have been shown to
have similiar activities (7, 19» 22, 56).

In work by

Fujimiya e^t al. , it was concluded that the NK cell in blood
v from infected patients was responsible for the direct lymphocytotoxicity observed against HSV-infected cells (19)•

This

cytotoxicity was demonstrated by incorporation of ^Icr into
target cells and measuring the amount of radioactivity
released after incubation with the lymphocytes (57).

In

Fujimiya's system, the effector cell lacked classical T cell
markers and was sensitive to trypsinization.

NK cells also

are cytotoxic to tumor cells as well as virus-infected
cells (2, 74).

NK tumor cell cytotoxicity was studied by

Wolfe et al. who concluded that the NK was the effector
cell from PC of BCG-infected mice because it was nonadherent.,
nonphagocytic, and lacked the theta Ag (74); furthermore
the activity of the NK cell was trypsin sensitive and
labile at 37°C.
Another type of nonphagocytic, nonadherent, non T or B
cell has been identified as a cytotoxic effector.

This

killer (K) cell, which functions only in the presence of
antibody (Ab), is responsible for an immunological mechanism
of resistance termed Ab-dependent-cell-mediated cytotoxicity
(ADCC) (41).

The K cell is similiar in physical character

istics to the NK cell, but requires IgG specific for the
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virus to function (4l).

Greenberg studied ADCC with non

adherent, nonphagocytic cells from individuals who had been
exposed to influenza virus and found that destruction of
influenza-infected cells occured only in the presence of
viral Ab (22).

When Ab was removed, the cytotoxicity was

greatly reduced.

In a similiar study by Galama, the K

cell was responsible for ADCC against measles-infected
target cells (20); ADCC does not appear, however, to be
exclusively associated with K cells (39).

MacFarlan demon

strated that in SFV infections, the Ab-dependent early
effector cells were macrophages and an Ab independent
NK cell appeared later in the infection (41).
Cytotoxicity also was studied by Rola-Pleszcznski
who demonstrated that human T lymphocytes, previously
sensitized to rubella virus, destroyed rubella-infected
baby hamster kidney (BHK-21) target cells without the
production of soluble lyrnphokines (57).

Inada et al. also

characterized a T-cell-mediated cytotoxicity system against
mouse adenovirus-infected targets (29).

In this system,

the cytotoxicity was present only when effector and target
cells were from animals which shared the same H-2 restiction,
but inhibition of viral replication was not limited to one
particular virus nor was interferon involved in the immuno
logical reaction.

T-cell cytotoxicity also was investigated

by Centifanto et_ al. in which the release of a lymphokine
was associated with the cytotoxic activity against HSVinfected monolayers (7).

This mediator, isolated after
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T cell incubation on infected monolayers, was not interferon.
In resolving the mechanisms of nonspecific immunity
against viral infections, several parameters must be con
sidered as potential solutions: these include increased
phagocytosis of virions by activated macrophages, cytotox
icity of viral target cells by immunological cells or med
iators, compartmentalization of infectious virus and the
production of interferon or other antiviral mediators.
One particular model to define these mechanisms has been
developed by Lodmell and Ewalt (39. 4-0).

In this system,

nonviable Mycobacterium tuberculosis, strain Jamaica,
suspended in an oil-in-saline emulsion, was used to induce
nonspecific resistance to encephalomyocarditis virus (EMCV)
infection (39).

The mycobacteria emulsion, when injected

i.p. or i.Vi, induced resistance to E.VIC.V challenge by any
of four routes; intramuscularly (i.m.), i.p., i.v., or s.c..
This viral resistance was maintained from 1-12 weeks postsensitization with the mycobacteria, and after EMCV challenge,
less than 50% of the surviving mice possessed circulating
anti-E;v'ICV Ab and none had detectable serum interferon.
Experiments to quantitate EMCV in the spleen, liver and
sera of normal and mycobacteria-sensitized mice indicated
that mice were protected by a mechanism which inhibited
early viral replication and spread of the virus to the CNS.
T-0 further characterize the mechanisms of protection
in this model, Lodmell and Ev/alt selectively removed or
temporarily inactivated various components of the immune
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system in vivo (40).

A rapid elimination of infectious

virus from the circulation by phagocytic cells did not
appear to be the mechanism of protection because similiar
concentrations of virus were found in sera of mycobacteriasensitized and normal mice from 1-120 minutes after EMCV
challenge.

Some of the mycobacteria-sensitized mice that

survived EMCV infection were viremic 72 h post-virus chalrlenge which indicated that the virus did replicate in these
mice.

Furthermore, mice splenectomized prior to sensiti

zation with mycobacteria were resistant to viral challenge,
whereas, splenectomies performed after mycobacteria admini
stration resulted in death of mice challenged with EMCV.
The spleen was postulated to harbor effector cells in mice
although in its absence, mycobacteria appeared to localize
in areas that were sufficient to enhance resistance to a
lethal challenge of EMCV.

In addition, neonatally thymec-

tomized mice or athymic nude mice sensitized with the
mycobacteria emulsion were resistant to EMCV.

When myco-

bacteria-sensitized mice were injected i.p. with silica,
a putative macrophage inactivator, resistance to EMCV was
abolished.

The number of macrophages and lymphocytes in

the PC population had decreased ninefold after silica treat*ment while the number of neutrophils doubled.

In addition,

i.p. administration of cyclophosphamide, an immunosuppressant,
2 days prior to virus challenge decreased the number of PC
threefold and abrogated resistance of mycobacteria-sensitized
mice to EMCV.

Thus, the effector cell based on these in
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vivo studies appeared to be a macrophage acting indepen
dently of T: cells.

The mode of action of these effector

cells was not clearly evident and in order to further
define this system of nonspecific resistance, studies were
continued in an in vitro tissue culture model (Lodmell and
Ewalt, personal communication).

In this tissue culture

system, EMCV-infected mouse embryo fibroblast (MEF)
monolayers were overlaid with unseparated peritoneal cells
(PC) from either mycobacteria-sensitized or normal mice
at a PC-to-MEF ratio of 20.

Cultures incubated with PC

from mycobacteria-sensitized mice were found to contain
significantly less virus at 18 h than those with PC from nor
mal mice (Pusateri, jet a^L. , manuscript accepted for publication).
The purpose of the research presented in this thesis
is to define the in vitro mechanisms for inhibition of EMCV
replication by PC from mice sensitized with nonviable
M. tuberculosis.

With this model, such factors as temper

ature, pH and replenishment of nutrients during the course
of infection will be monitored for their effects on viral
replication.

Enhancement of viral inhibition will be

attempted by varying doses of mycobacteria, collection of
PC at different intervals after the injection of the myco
bacteria emulsion, and using different MEF monolayers for
the assay in order to define the parameters for maximal
in vitro inhibition.

Furthermore, kinetic studies will

determine the interval necessary for contact between effector
cells and infected MEF cells to inhibit viral replication.
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Various multiplicities of EMCV infection and cytotoxicity
assays will be done to determine the importance of viral
spreading to uninfected monolayers.

Athymic nude mice

will be administered the mycobacterial emulsion and their
PC tested in vitro.

Furthermore, supernatant fluids from

PC cultures will be screened for antiviral mediators and if
found, the active factor(s) will be characterized.
The present experiments show that PC from mice sensi
tized 2-10 weeks previously with 50-500 ug of mycobacteria
inhibit EMCV replication when incubated at a 20:1 effectorto-target cell ratio on MEF monolayers infected with 5-7
plaque forming units (PFU) of EMCV.

Kinetic studies indicate

that PC and infected MEF must be in contact for 8-10 h be
fore detectable (> 1 log^g or > 90%) inhibition is observed.
Inhibition of EMCV replication is not due to unfavorable
in vitro environmental conditions nor due to cytotoxicity
of monolayer cells, yet EMCV is prevented from spreading
to uninfected MEF cells.

PC cultures from mycobacteria-

sensitized mice have been found to produce an immune (type II)
interferon that is similiar, but not identical to classical
type II interferon.

It appears that the immune interferon

is responsible for the nonspecific inhibition of EMCV
replication.

MATERIALS AND METHODS

Mice

All mice were derived from stocks maintained

at the Rocky Mountain Laboratories (RML), Hamilton, MT.
One to three month old C57BL/lOScN mice, unless noted other
wise were used for mycobacteria sensitization.

Mouse

embryo fibroblasts monolayers (MEF) were prepared from
Carworth Farms Webster mice (CFW/R) and 19-21 day old
Swiss Webster mice were used to prepare an encephalomyocarditis virus (EMCV) pool.

BALB/c (nu/+) and athymic

(nude) mice (nu/nu, produce by successive cross-intercross
ing onto a BALB/c backround) were used in some sensitization
studies.

The nude mice were maintained in a special animal

room in conventional autoclaved cages with filter caps,
sterilized bedding and water bottles.

Sterilized food and

water were supplied ad libitum.
Preparation of Mycobacterial Emulsion

Acetone dried

Mycobacterium tuberculosis, strain Jamaica, was provided
by Dr. Carl Larson, University of Montana, Missoula, MT.
The culture was isolated from a fatal case of tuberculosis
in 1933 by Drs. J. Freund and E. Opie (personal communication,
Dr. George Kubica, Center for Disease Control, Atlanta, GA).
Twenty-five mg of autoclaved and heat-dried mycobacteria
was suspended in 8 drops of a sterile light mineral oil
(Drakeol 6VR, Pennsylvania Refining Co., Butler, PA).

This

suspension was ground to a smooth consistency using a drill
press rotating at 800 RPM in a sterile tissue grinder
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equipped with a Teflon pestle (Scientific Glass Apparatus
Co., Inc., Bloomfield, N.J.).

After heating the mixture for

5 min at 75°C, 10 ml of preheated (75°C) 0.15M NaCl with
0.2% tween 80 was added, and the mixing v/as continued for
another 5 min.

Finally, the uniform emulsion was heated

to 65°C for 30 min.

<i/hen properly prepared, the mycobacteria

were associated with the oil droplets.

Viable mycobacteria

were not detected after culturing the emulsion on Dubos
plates.
Sensitization of Mice with Mycobacteria

C57BL/lOScN

mice were injected i.p. or i.v. with 0.2 ml of the oil
emulsion which contained 500 ug of mycobacteria, unless
otherwise noted.

Control mice were either untreated or

injected with the oil emu Is.ion without mycobacteria (TSO).
Viruses
Bethesda, MD.

EMCV was obtained from Dr. Michael Ross, NIH,.
A stock pool was prepared by the intracerebral

(i.e.) injection of 19-21 day old Swiss Webster mice with
2 x 10-^ PFU/0.03 ml.

Twenty-four hours later, the brains

were harvested, weighed, homogenized in a blender and frozen
in one ml quantities at -70°C.

The stock EMCV preparation

contained 9.5 x 10^ PFU/ml.
Vesicular Stomatitis Virus (VSV), Indiana strain, ob
tained from the American Type Culture Collection, Rockville,
MD was grown and assayed in primary rabbit kidney (PRK) and
mouse L (ML) cells.

The stock pool contained 1 x 10^ PFU/ml

in PRK cells and 1 x 10^ PFU/ml in ML cells.
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Herpes Simplex Virus, type 2 (HSV-2), strain 196 ob
tained from Dr. Carl Larson, University of Montana, Missoula,
MT was prepared and assayed on PRK cells and contained
2.6 x 10? PFU/ml.
Vaccinia Virus (VV), strain MR69-2, also obtained from
Dr. Larson, was grown and assayed on PRK cells, and had a
titer of 7.2 x 10^ PFU/ml.
Media

Media for growing tissue culture cells consisted

of Eagle Minimal Essential Media (MEM) (Grand Island Bio
logical Co., Grand Island, N.Y., catalog #F-15) containing
10% fetal calf serum (FCS), 200 units/ml of penicillin G
(Eli Lilly and Co., Indianapolis, IN), and 1 ug/ml of
amphotericin B (E.R. Squibb and Sons, Inc., Princeton, N.J.)
(MEM-10).

Dilutions of MEM-10 were made in MEM without

FCS and were used in different assays.
buffered saline (PBS) with Ca

and Mg

Dulbecco's phosphate
was used to wash

monolayers and cell suspensions.
Tissue Culture Cells

Primary mouse embryo fibroblasts

(MEF) were prepared from CFW/R mouse embryos.

After re

moval of heads, arms, legs and tails, the remaining torsos
were cut into small sections which were suspended in 100 ml
of 0.25% trypsin (Difco trypsin 1:250, Detroit, MI) in
Dulbecco's PBS with 2% FCS.

The suspension was trypsinized

at 4°C for 18-24 h in a 200 ml trypsinizing flask and then
was strained through sterile gauze into 4-50 ml centrifuge
tubes containing 5 ml of FCS.

After centrifugation at

300 x g for 10 min and two washes with 50 ml of MEM-10,
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10-15 ml of 0.63^ tris NH^Cl was added to the cells to
lyse erythrocytes.

The cells were held at room temperature

for 5-10 min, diluted with 35-^0 ml of MEM-10 and the cells
centrifuged again.

A stock pool of MEF' cells was prepared

by planting 1 x 10^ cells/ml in 40 ml of MEM-10 in a 150 cm^
tissue culture flask (Corning, Corning, N.Y.).

Monolayers

which were confluent in 7-10 days were harvested from the
flasks by incubating the cells at 37°C in 5% 00g in air
for 10 min in 35 ml of a saline A, trypsin, and versine (STV)
solution consisting of 0.8% NaCl, 0.04% KC1, 0.1% dextrose,
0.058% NaHCO^, 0.05% trypsin and 0.02% versine.

The cell

suspension was added to a 50 ml centrifuge tube with 5 ml
of FCS and centrifuged at 300 x g for 10 min.

Cells were

washed twice in MEM-10 and resuspended in MEM supplemented
with 20% FCS and 10% dimethyl sulfoxide (DMS0) (J.T. Baker
Chemical Co., Phillipsburg, N.J.) (4 ml/150 cm^ flask).
One ml of the cell suspension was distributed into ampoules
(Wheaton Scientific, Milleville, N.J.) and sealed with a
Hp and Op torch.

The ampoules then were precooled in a

95% alcohol bath at -70°C for 4-24 h and subsequently
stored in liquid Np.

Secondary MEF cells were used for the

in vitro viral inhibition and interferon assays by adding
the cells from one ampoule to 25-75 ml of MEM-10 and distri
buting one ml quantities of this solution into the wells of
a TC-24 plate (16 mm diameter wells, Linbro, Division of
Flow Laboratories, Hamden, CT).

Monolayers were confluent

after 2-4 days of incubation at 37°C in 5% OO2 in air.
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Viral titrations were performed in the following cells*
Mouse L (ML) cells, provided by Dr. R.K. Gerloff,
ML, Hamilton, MT, were used for VSV, EMCV, and interferon
titrations.

The cells from one freezing ampoule were diluted

in 75-300 ml of MEM-10 and planted in TC-24 plates as with
the MEF; monolayers were confluent in 1-3 days.
PRK cells, provided by Larry Ewalt, RML, Hamilton, MT,
were used for HSV and VV titrations.
The following tissue culture cells also were used
during the course of the investigation:
Baby hamster kidney (BHK-21) cells were obtained from
Grand Island Biological Co., Grand Island, N.Y..
Primary chick embryo fibroblasts (CEF) were supplied
by Mort Peacock, RML, Hamilton, MT.
CER (chick embryo cells contaminated with hamster
embryo cells) were provided by Dr. Abigail Smith, Yale
University,, New Haven, CT.
Crandell feline kidney (CRFK) cells were provided by
Dr. David Porter, UCLA School of Medicine, Los Angeles, CA.
Human embryo kidney (HEK) cells were supplied by Dr.
Richard Ushijima, Department of Microbiology, University of
Montana, Missoula, MT.
VERO (African green monkey kidney cells) were purchased
from the American Type Culture Collection (#CCL-8l).
Stock pools of the tissue culture cell lines (ML, BHK-21,
CER, CRFK, HEK, and VERO) were prepared by diluting the cells
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from one freezing ampoule into a 150 crrT flask containing
40 ml of MEM-10 and incubating the flasks at 37°C in 5f°
COp in air until a confluent monolayer was present.

The

cells were removed with 35 ml °f STV as before, placed in
a 50 ml centrifuge tube with 5 ml of FCS and centrifuged
at 300 x g for 10 min.

The cell pellet was resuspended

in 10 ml of MEM-10, distributed in 1 ml quantities to
150 cm^ flasks containing 40 ml of MEM-10 and the cells
were incubated until monolayers were confluent.

The cells

then were frozen in ampoules as described previously.
PC Harvest

Mice were killed by spinal dislocation

and injected i.p. with 4-5 ml of Dulbecco's PBS containing
5 units of heparin per ml.

After massage, the peritoneum

was pierced over an open centrifuge tube and the cells and
washings collected.

PC from individual mycobacteria-

sensitized, TSO-injected, or normal mice were collected
in separate pools and Dulbecco's PBS with heparin was added
to equilibrate the volumes.

The PC were centrifuged at

300 x g for 5 min at 4°C, washed in Dulbecco's PBS, and
5 ml of prewarmed (37°C) 0.83'% tris AH^CI was added.

After

the cells had been incubated for 5 min at room temperature,
the tris NH^Cl was diluted in Dulbecco's PBS.

The cells

then were centrifuged as before and resuspended at a con
centration of 5 x 10^ PC/ml in MEM plus 2% FCS (MEM-2).
Trypan blue exclusion determinations indicated that the
PC were consistently

> 90% viable.
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Spleen Cell Harvest

Spleens were removed from myco

bacteria-sensitized or normal mice and held in Dulbecco's
PBS with heparin before the cells were gently scraped from
the splenic sac with small sterile curved forceps.

The

entire solution then was placed in a 50 ml centrifuge
tube and the larger fragments of spleen were allowed to
settle for 5 min.

The remaining cell suspension was poured

into a fresh centrifuge tube and a series of washes and
lysis of erythrocytes was performed as with the PC.

Spleen cells were resuspended in MEM-2 at 5 x 10^ cells/ml.
Trypan blue staining indicated that the cells were > 90 /o
c

viable.
In Vitro Viral Inhibition Assay

MEF monolayers in

TC-24 plates were infected with 5-7 PFU of EMCV in 0.2 ml
of MEM.

After adsorption for 2 h at 37°C. in 5$ OOp in

air, the EMCV was aspirated and the monolayers were washed
with Dulbecco's PBS.

Unless otherwise noted, PC from mice

injected 2-6 weeks previously with mycobacteria or PC from
normal mice, suspended in 1 ml of MEM-2 were added to in
fected monolayers at a PC-to-MEF ratio of 20 (5 x lO^PC).
After incubation for 18 h at 37°C in 5% C02 in air, entire
cultures were harvested by scraping the cells from the
plastic wells with the plunger of a sterile plastic dis
posable 1 cc tuberculin syringe.
-70°C before titration.

Samples were frozen at

Duplicate samples were included in

all assays and each experiment was conducted a minimum of
three times.
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Virus Titrations

EMCV, VSV, and VV were titrated in

plaque assays utilizing a 0.75$ methocellulose (Fisher
Scientific Co., Fair Lawn, N,J.) in MEM-10 as an overlay
media to prevent secondary plaquing.

The overlay media

was prepared by separately sterilizing 3 g of methocellulose
and 200 ml of distilled water and combining the two immed
iately after autoclaving.

After 2 h of mixing at 60°C,

the media was cooled to 40°C and 200 ml of prewarmed 2X
MEM-10 was added.

The entire solution then was spun for

another 2 h at room temperature and cooled at 4°C overnight.
To titrate virus, a series of 10 fold dilutions were made
for each sample in MEM and 0.2 ml of each dilution was used
to infect duplicate ML (for EMCV or VSV) or PRK (for VV)
monolayers in TC-24 plates.

After a 2 h adsorption period

the virus was aspirated and monolayers were washed with
Dulbecco's PBS and overlaid with the methocellulose media.
Twenty-four hours post-infection (for EMCV) or 48 h post
infection (for VSV or VV), the overlay media was aspirated
and monolayers were washed with Dulbecco's PBS, fixed with
95fa alcohol, and stained with a 0.8$ giemsa solution pre
pared in 50$ methanol and 50$ glycerol.

Plaques were

counted and titers expressed as PFU/0.2 ml, log10.
HSV-2 titrations were similiarly done in FRK cells but
MEM-10 supplemented with 2% human sera containing HSV anti
bodies was used as the overlay media.
fixed and stained at 48 h.

Monolayers were
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Killing of PC

PC were killed either by heating at

56°C for 30 min or sonication with a Bronwill Biosonik III
for 45 seconds at maximum intensity.
viable after either treatment.

The cells were

10$

Media in which the cells

were lysed also was tested for antiviral activity.
pH Determinations

The pH of various MEF cultures was

recorded with a standard pH meter (Beckman-Expandomatic IV)
18 h post-infection and just prior to harvest of cultures.
Measurements were done quickly to avoid pH changes that
result when cultures are brought from an enriched COp
environment into the atmosphere.

To avoid cross contam

ination, the electrode was cleaned with 70$ alcohol between
measurements.
Supernatant Fluid Preparation

PC from mycobacteria-

sensitized or normal mice suspended in MEM-2 at a concentration of 5 x 10

cells/ml were incubated at 37°C in

5$ COp in air in 35 mm plastic tissue culture dishes
o

(Corning, Corning, N.Y.) or 25 cm

tissue culture flasks

(Co-Star, catalog #220-46, Cooke Laboratory Products,
Alexandria, VA).

At 18 h, unless stated otherwise, the

supernatant fluids were removed, centrifuged at 300 x g for
5 min at 4°C and stored at -30°C.

Supernatant fluids were

diluted ls2 (unless stated otherwise) in MEM-2 and tested
in interferon assays or for antiviral activity on EMCVinfected MEF monolayers.
Peritoneal Wash Preparation

The Dulbecco's PBS plus

heparin washings used to harvest PC from mycobacteria-sensi-
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tized or normal mice were concentrated 10-20 fold by vacuum
pressure at 4°C after removal of the FC.

Concentrated

fluids subsequently were diluted 1:2 in MEM plus 4$ FCS
(MEM-4) and tested for antiviral activity on EMCV-infected
MEF monolayers.
Mouse Serum Collection

Mice anesthetized with ether

were bled from the brachial artery.

Blood from mycobacteria-

sensitized or normal mice was pooled, held at room temper
ature for 30-60 min and then centrifuged at 1550 x g for
15-30 min.

Serum was removed and heat inactivated for

30 min at 56°C before storing at -5°C.

Dilutions of serum

in MEM were tested for interferon and antiviral activity on
EMCV-infected MEF monolayers.
Replenishment of Culture Nutrients During EMCV Infection
EMCV-infected MEF monolayers, incubated with 1 ml of PC
(5 x 10^ PC) from mycobacteria-sensitized or normal mice
or 1 ml of MEM-2 alone, were refed with 1 ml of fresh MEM-2
at 5 or 10 h post-infection or with 0.5 ml of fresh MEM-2
at both 5 and 10 h post-infection.

Entire cultures were

harvested and titrated as usual.
Refeeding PC Cultures from Mycobacteria-Sensitized Mice
for Supernatant Fluid Harvest

Supernatant fluids harvested

from 18-24 h PC cultures were prepared as previously des
cribed with the exception that after the fluids were
removed and centrifuged, nonadherent cells remaining in the
pellet and adherent cells on the flask were washed with
Dulbecco's PBS.

All the cells were subsequently resuspended
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in a similiar amount of fresh MEM-2 as was removed and
reincubated.

This procedure was repeated every 18-24 h

for a week.
Interferon Assay

Supernatant fluids from PC cultures

of mycobacteria-sensitized or normal mice and serum from
similiar mice were assayed for interferon on ML and MEF
cells.

In all assays, two standard type I interferons

were used; the first was a reference sample prepared in
murine L929 cells by inoculation with Newcastle Disease
Virus (NDV) and contained 1600 units/ml (Lot #G002-904-511.
supplied by the
Bethsada, MD).

Research Resources Branch, NIAID, NIH,
The second standard type I interferon,

prepared at RML, was sera harvested from mice 2 h following
i.v. inoculation with 50 ug of poly (I)-poly (C) (from the
Research Resources Branch); this type I interferon contained
4000 units/ml.

Two standard type II immune interferons

also were included in these assays.

One was obtained from

Dr. Ruth Neta (University of Notre Dame, Notre Dame, IN)
and v/as prepared in mycobacteria-sensitized mice that were
challenged i.v. with old-tuberculin (OT); it contained
800 units/ml.

A second standard type II interferon was

provided by Dr. Jerzy A. Georgiades, (University of Texas
Medical Branch, Galvaston, TX) and contained 10 units/ml.
To perform the assay, 0.5 ml of the various fluids at
similiar concentrations of activity were overlaid on unin
fected MEF or ML monolayers in TC-24 plates and incubated
for 24 h (unless otherwise noted) at 37°C in 5$ COp in air.
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The fluids then were removed and the monolayers were washed
with Dulbecco's PBS and challenged with 10-15 PFU of either
EMCV or VSV.

After a 2 h viral adsorption, the monolayers

were washed and overlaid with methocellulose and the plates
were incubated at 37°C in 5$ 00 2 in air for 20-24 h (for
EMCV) or 48 h (for VSV).

The plates were fixed and stained

as before for plaque enumeration.

A fluid was considered

positive for interferon activity if it inhibited plaque
formation by > 50$ as compared to viral control wells
incubated without an interferon sample.

Interferon titers

were expressed as the reciprocal of the highest dilution
of the supernatant fluid that inhibited plaque formation
by 50$.
Characterization of the Mediator in Supernatant Fluids
Antiviral activity in supernatant fluids containing similiar
units of activity was characterized as follows: 1) Acid
stability was measured by dialyzing samples for 24 h at
4°C against 1 liter of 0.1M pH 2 glycine HC1 buffer.

After

24 h the acid buffer was removed and 1 liter of Dulbecco's
PBS (pH 7.2-7.4) v/as added.

The fluids were dialyzed for

another 24 h at 4°C before they were removed from the dialysis
tubing. 2) Heat stability consisted of heating fluids at
56°C for 0.5. 1 and 2 h.

3)

Trypsin sensitivity was deter

mined by incubating the fluids v/ith 1.25 mg/ml of trypsin
for 5 h at 37°C.
0.5 ml of FCS.

The trypsin v/as inactivated by adding

4)

Size estimations of the active molecule

were done by filtering the fluid through a 0.22 u filter
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(Swinnex catalog #SXGS 025 LS, Bedford, MA) and by ultracentrifugation at 100,000 x g for 1 h.

5)

Ten to 20 fold

concentrations were done in dialysis tubing under vacuum
pressure at 4°C.
After each treatment, the samples were diluted 1:2
in MEM-4 (for #1), or in MSM-2 (for #2, 3 and 4) or MEM
(for #5) and assayed for interferon activity on MEF or ML
cells as described previously.
Preparation of Supernatant Fluids in PC Cultures In
cubated with old-tuberculin (0T) or Purified Protein Deriva
tive (PPD)

Supernatant fluids were prepared with PC from

mycobacteria-sensitized mice or normal mice as previously
described with the exception that cultures were incubated
with either 50 ug of OT (Jensen-Salsbery Laboratories,
Kansas City, MO) or 50, 100 or 500 ug of PPD (Parke, Davis
and Co., Detroit, MI).

Controls consisted of PC incubated

without the mycobacterial antigens or MEM-2 incubated with
various amounts of OT or PPD.
Cytotoxicity Assay

Uninfected MEF monolayers were

labeled with ?. uCi of Nap^CrO^ (New England Nuclear, Boston,
MA) in 0.2 ml of MEM for 2 h at 37°C in 5$ C02 in air.

After

incorporation of the radiolabel, the monolayers were washed
three times with Dulbecco's PBS and either infected with
5-7 PFU of EMCV in 0.2 ml of MEM or overlaid with 0.2 ml of
MEM alone.

Two hours later, monolayers were washed and over

laid with PC from mycobacteria-sensitized and normal mice
or supernatant fluids harvested from K! cultures from sim-
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iliar mice.

Eighteen hours later, the culture fluids from

all samples were harvested, centrifuged at 300 x g

for

10 min and 0.5 ml of fluid was assayed in a gamma counter
(Nuclear Chicago) to determine the amount of ^lgr present.
The maximum amount of ^Cr that could be released from the
monolayers was determined by incubating monolayers with
MEM-2 and harvesting the cultures in their entirity.

These

samples were frozen and thawed three times, spun at 300 x g
for 10 min and 0.5 ml of fluid was assayed in the gamma
counter.

To calculate the percent of 5^-Cr released, the

amount of ->*Cr measured in the samples overlaid with PC or
supernatant fluids was divided by the maximum amount of
^Cr that was released by freezing and thawing of the cells.
EMCV Neutralization Assay

Thirty PFU of EMCV in 0.3 ml

MEM was incubated at 37°C with an equal amount of an un
diluted or a 1:2 dilution of an active supernatant fluid
for 1, 2, 4, 8, 12, 18 and 24 hours.

After incubation the

samples were titrated for EMCV in ML cells.

Controls con

sisted of EMCV incubated with supernatant fluids from PC of
normal mice or media alone.
Anti-Interferon Assay

Rabbit anti-type I and anti

type II mouse interferon antibodies were tested in a
neutralization assay with supernatant fluids from PC cultures
of mycobacteria-sensitized mice.

Rabbit anti-L cell inter

feron globulin (anti-type I interferon) was supplied by
Dr.June Dunnick, Development and Application Branch, Micro
biology Infectious Disease Program, NIAID, NIH, Bethesda, MD,

and rabbit anti-mouse type II interferon was supplied by
Dr. Jerzy A. Georgiades, University of Texas Medical branch,
Galvaston, TX.

Anti-interferon antibodies were diluted in

MEM-2 to concentrations that neutralized 10 units of homo
logous interferon; normal rabbit globulin (NRG) was used
as a control at similiar concentrations.

Supernatant

fluids and known type I and type II interferons were diluted
to 1-4 units/0.11 ml and incubated at 37°0 for 30 min with
0.11 ml of the antisera or NRG.

One-tenth ml of these

mixtures then were incubated on duplicate uninfected MEF
monolayers in TC-96 plates (6 mm diameter, Linbro Scientific,
Inc., Flow Laboratories, Hamden, CT) for 24 h at 37°C in
5$ COp in air before they were challenged with 10-15 PFU of
VSV/0.025 ml.

Because of the small size of the monolayer

wells, plates were fixed and stained for plaque enumeration
at 24 h rather than the usual 48 h.

Interferon activity

was expressed as > 50$ reduction in the number of plaques
present in virus-infected control wells.

RESULTS
Inhibition of E:.;iCV replication by PC from mice sensi
tized with nonviable M. tuberculosis.

The data in Table 1

indicate that PC from mice sensitized with 500 ug of
M. tuberculosis, as compared to PC from normal mice, inhibit
EMCV replication when incubated with infected MEF monolayers
at a PC-to-MEF cell ratio of 20; viral replication was
inhibited by> 2 log^Q or > 99% with PC from mice sensitized
either i.p. or i.v. with mycobacteria.

At lower PC-to-MEF

cell ratios, PC from i.p. sensitized mice were more effect
ive.

PC from mice injected with the oil emulsion without

mycobacteria were not inhibitory (data not shown).

In view

of these results, all subsequent experiments, unless noted
otherwise, were done with PC from i.p. sensitized and un
treated mice at PC-to-MEF cell ratios of 20.

Inhibition of EMCV replication by PC from mice sensi
tized with various concentrations of nonviable M. tuberculo
sis.

In an attempt to enhance the inhibition of viral

replication, various concentrations of mycobacteria were
administered i.p. and PC were tested three weeks later in
the inhibition assay.

The data in Table 2 demonstrate that

inhibition was not dose dependent; that is, doses of 50-500
ug of mycobacteria were equally effective.

Because previous

in vivo studies utilized $00 ug of mycobacteria in the
emulsion for sensitization (39), for consistency the same
concentration was used for the remainder of these studies.
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TABLE 1

Inhibition of EMCV Replication by PC from Mice
• (a)
Sensitized with Nonviable M. tuberculosis^ '

Route of M.
tuberculosis

Effector to Target Cell Ratio
20

5

(PFU/0.2 ml, log10)

injection

i.p.

4.1

4.3

5.1

i.v.

4.0

5.2

6.2

6.4

6.3

6.4

none, Normal PC

(a)

10

MEF monolayers that had been infected for 2 h with 5-7

PFU of EMCV were incubated with different concentrations
of PC from normal mice or mice that had been injected with
500 ug of mycobacteria 3 weeks previously.

After 18 h

incubation, entire cultures were harvested and titrated
for virus.

In the absence of PC, the virus titer was

106,4 PFU/0.2 ml, log10.
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TABLE 2

Inhibition of EMCV Replication by PC from Mice

Sensitized with Different Concentrations of Nonviable
(a)
M. tuberculosis

ug of M. tuberculosis

Inhibition of EMCV
Replication, log10^b^

per mouse

50

2.0

100

2.9

250

2.3

500

2.5

1000

1.7

none, Normal PC

(a)

none

MEF monolayers that had been infected for 2 h with

5-7 PFU of EMCV were incubated at a PC-to-MEF ratio of 20
with PC from normal mice or mice that had been sensitized
i.p. 3 weeks previously with various concentrations of non
viable mycobacteria,,

Cultures were harvested 18 h after

infection and virus titers determined.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers of cultures incubated with PC from
normal and mycobacteria-sensitized mice.

Cultures incubated

without PC had viral titers comparable to cultures incubated
with normal PC.
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Inhibition of viral replication with PC harvested at
different intervals post-mycobacteria sensitization.

Prior

in vivo experiments have shown that mice were protected
against a lethal challenge of EMCV from 1-12 weeks after
administration of the mycobacterial emulsion (39).

To

determine the intervals that PC from mycobacteria-sensitized
mice were effective in vitro. PC were removed from mice at
various times post-mycobacteria sensitization.

The data in

Table 3 indicate that PC from mice sensitized i.p. 2-10
weeks previously with 500 ug of mycobacteria markedly
inhibit viral replication (_> 1 log1Q or > 90%); maximal
inhibition occurs with PC. harvested 2-6 weeks post-sensitization.

It has been possible, however, to demonstrate

inhibition of viral replication with PC from some mice
that were sensitized 15 weeks previously with mycobacteria.
Hereafter FC were harvested for experiments 2-6 weeks
post-mycobacteria sensitization.

Effects of various temperatures on in vitro inhibition
of EMCV replication.

To determine whether PC from myco

bacteria-sensitized mice would be more effective if the
rate of EMCV replication was reduced, an attempt to slow
viral growth was made by incubating infected monolayers
with PC from mycobacteria-sensitized mice at lower temper
atures.

The data in Table 4 indicate that at the lower

temperatures of 30.5°C or 33°C. 1.2 and 1.0 l.og10 of inhibi
tion was observed.

In contrast, at 37°C, inhibition of

TABLE 3

Inhibition of EMCV Replication by PC Harvested at

Various Intervals After Sensitization with Nonviable 14^
. (a )
tuberculosis^ '

Weeks post-injection
of mycobacteria

(a)

Inhibition of EMCV
Replication, log-j^13^

1

0.4

2

2.4

3

2.2

4

2.1

5

1.5

6

2.0

7

1.4

8

1.3

10

1.0

15

0.4

20

0.1

MEF monolayers that had been infected 2 h previously

with 5-7 PFU of EMCV were incubated at PC-to-MEF ratios of
20 with PC from normal mice or mice that had been injected
i.p. with 500 ug of nonviable mycobacteria.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers of cultures incubated with PC from
mycobacteria-sensitized and age-matched normal mice.

Cul

tures incubated without PC had viral titers comparable to
monolayers incubated with normal PC.
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TABLE 4

Effect of Temperature on Inhibition of EMCV Repli-

(a )
cation by PC from Mycobacteria-Sensitized Micev '

Temperature
(°C)

PC Source
Mycobacteria-

Normal

Inhibition
None

sensitized

of EMCV
Replication
(log10)(b)

(PFU/0.2 ml, log1&)

30.5

3.7

4.9

5-0

1.2

33

4.4

5.4

5.3

1.0

37

3-5

5-7

6.0

2.2

(a)

MEF monolayers that had been infected 2 h previously

with 5-7 PFU of EMCV were incubated at different tempera
tures with media or PC at PC-to-MEF ratios of 20.

Cultures

were harvested 18 h after infection and virus titers deter
mined.
(b)

Inhibition of EMCV replication v/as determined by com

paring virus titers of cultures incubated at similiar
temperatures with PC from normal and mycobacteria-sensitized
mice.
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viral replication was 2.2 log^Q.

Furthermore, it is shown

that EMCV replication in cultures without PC also was max
imal at 37°C.

Thus, it appears that the optimal conditions

for both viral growth and the inhibitory functions of PC
is 37°C.

Hereafter all experiments were done at this

temperature.

Effect of PC from mycobacteria-sensitized C57BL/lOScN
mice on EMCV replication in MEF monolayers prepared from
different strains of mice.

MEF monolayers were prepared

from three strains of mice to determine if there was a
variation in the inhibition of EMCV replication in the
different cells.

Outbred Swiss Webster, inbred C57BL/lOScN

and outbred CFW/R mouse embryo fibroblasts were infected
with 5-7 PFU of EMCV and incubated with PC from mycobacteriasensitized and normal C57BL/lOScN mice.

The data in Table 5

show that maximum inhibition was observed in CFW/R mono
layers (> 99cf° inhibition) and that monolayers prepared from
the syngenic C57BL/lOScN were less effective, although the
inhibition was > 90%.

CFW/R monolayers were used in all

subsequent assays.

Effect of pH on inhibition of EMCV replication.

EMCV is

classified as a cardiovirus in the family Picornaviridae
based on a number of characteristics, among which is
stability at pH 3 or 8, but lability at pH 6 (17).

Because

PC may have been affecting the pH of the tissue culture

TABLE 5

Effect of PC from Mycobacteria-Sensitized C57BL/lOScN

Mice on EMCV Replication in MEF Monolayers Prepared from DifiV
erent Strains of Mice^a^

Strain of Mouse
MEF Monolayer

Source of PC
MycobacteriaSensitized

Inhibition

Normal

of EMCV

C57BL/lOScN

C57BL/lOScN

Replication
(lc.g10)(b)

(PFU/0.2 ml, log10)

CFW/R

3.5

6.3

2.8

RML

4.3

6.5

2.2

5.1

6.8

1.7

C57BL/lOScN

(a)

MEF monolayers prepared from different strains of mice

were infected with 5-7 PFU of EMCV for 2 h and then incu
bated at a PC-to-MEF ratio of 20 with PC from C57BL/lOScN
normal or similiar mice which had been sensitized 3 weeks
previously with 500 ug of mycobacteria.

eighteen hours later,

cultures were harvested and the virus titers determined.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers of cultures incubated with PC from mycobacteria-sensitized mice and normal mice.

Monolayers without

PC had viral titers comparable to cultures with normal PC.
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assay through their metabolic processes which ultimately
would result in an acid media, the pH of the media on
infected monolayers overlaid with media only or PC from
mycobacteria-sensitized or normal mice was recorded after
18 h of incubation at 37°C in 5% COg in air.

As observed

in Table 6, the pH of cultures incubated with PC or with
media alone were either 7.2 or 7.4 which are optimal for
EMCV replication.

The virus concentration in these cultures

differed, however, in that there was 2.0 log^Q less virus
in monolayers incubated with PC from mycobacteria-sensitized
mice as compared to PC from normal mice.

Effect of nutrient replenishment on inhibition of
EMCV replication by PC from mycobacteria-sensitized mice.
To further substantiate that PC do not inhibit viral repli
cation by causing an unfavorable environment for virus
growth, cultures were refed with fresh MEM-2 at various
times post-infection (Table 7).

The data demonstrate

that PC from mycobacteria-sensitized mice inhibited EMCV
replication whether or not the cultures were refed with
fresh media.

In fact, a slight enhancement of viral in

hibition was observed in the refed cultures.

Effect of nonviable PC from mycobacteria-sensitized
mice on EMCV replication.

To determine if nonviable PC.

from mycobacteria-sensitized mice inhibited EMCV replication,
PC were rendered nonviable by heating for 30 min at 56°C

TABLE 6

Effect of pH on Inhibition of EMCV Replication by
(a)
PC from Mycobacteria-3ensitized Mice

Source of PC

pH of Culture

PFU/0.2 ml

Media

ioglO

sensitized

V.2

4.0

Normal

7.2

6.0

None

7.4

6.7

-

Mycobacteria-

(a)

MEF monolayers that had been infected for 2 h with 5-7

PFU of EMCV were washed and then incubated with media or PC
at a PC-to-MEF ratio of 20.

Eighteen hours post-infection,

the pH of the cultures was determined, the cultures har
vested and virus titers determined.
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TABLE 7

Effect of Nutrient Replenishment on Inhibition of

EMCV Replication by PC from Mycobacteria-Sensitized Mice^a^

Time Post-In
fection Media

Source of PC
Myco-

Added to

bacteria-

Cultures

Sensitized

Normal

Inhibition
None

of EMCV
Replication
iog10(b)

(PFU/0.2 ml, log10)
5 h

4.0

6.3

6.3

2.3

10 h

4.1

6.1

6.2

2.0

5 & 10 h

4.2

6.2

6.3

2.0

none

3-9

5.7

5.5

1.8

(a)

MEF monolayers that had been infected for 2 h with 5-7

PFU of EMCV were incubated with media or PC at a PC-to-MEF
ratio of 20.

At the intervals noted 1 ml of fresh media

was added to the cultures, or 0.5 ml of fresh media was
added to cultures at 2 different times.

Eighteen hours post

infection, cultures were harvested and virus titers determined.
(b)

Inhibition of EMCV replication was determined by com

paring virus titers between cultures incubated with PC
from normal and mycobacteria-sensitized mice in the different
test groups.
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or rupturing the cells by sonication for 45 seconds with
Bronwill Biosonik III at maximum intensity.

The data in

Table 8 indicate that nonviable PC at a PC-to-MEF ratio
of 20 did not inhibit Ei'vlCV replication.

Furthermore, media

in which the PC were rendered nonviable also were ineffec
tive (data not shown).

Kinetics of viral inhibition by PC from mycobacteriasensitized mice.

To determine how rapidly PC from myco

bacteria-sensitized mice exert their inhibitory effects,
infected MEF monolayers were incubated with PC, and at
different intervals thereafter, entire cultures were har
vested and virus titers determined.

The data in Figure 1

indicate that significant viral inhibition (1 log10 or 90%)
was not observed until 12 h post-EMCV infection, or 10 h
after addition of PC to the monolayers.

Maximal viral

inhibition (2 log^Q or 99%) was seen at 18 h post-infection.
Monolayers incubated with PC from normal mice, or with media
alone, followed similiar patterns of viral growth through
out the 18 h incubation period.
To determine the minimal time PC had to be incubated
with infected monolayers to inhibit EMCV replication, PC
were added to monolayers at different intervals after in
fection, and all cultures were harvested 18 h post-infection.
MEM-2 incubated with the infected monolayers in which addi
tion of the PC was delayed, was not removed prior to
addition of PC.

The data in Figure 2 show that PC from

TABLE 8

Effect of Nonviable PC from Mycobacteria-Sensitized
Mice on Inhibition of EMCV Replication^^

Treatment

none

PC Source

Viability

mycobacteria

PFU/0.2 ml,log10

4.7

56°C, 30 min

mycobacteria

0%

6.2

sonication

mycobacteria

10%

6.1

100%

5.8

none

(a)

normal

MEF monolayers that had been infected for 2 h with 5-7

PFU of EMCV were incubated at an PC-to-MEF ratio of 20 with
viable PC from normal mice or viable or nonviable PC from
mice sensitized with 500 ug of mycobacteria.

The PC were

rendered nonviable by heating for 30 min at 56°C or sonica
tion for 45 seconds with a Biosonik III at maximum intensity.
Eighteen hours later the cultures were harvested and virus
titers determined.

In the absence of PC, the virus titer

3
was 10PFU/0.2
ml, 1°S10.
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Kinetics of Viral Inhibition by PC from ivlycobacteriaSensitized Mice

Monolayers that had been infected with 5-7 PFU of EMCV v/ere
incubated with PC at a PC-to-MEF ratio of 20.

At different

times after infection, entire cultures were harvested and
virus titers determined
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EMCV Replication in Monolayers Incubated with PC from

Mycobacteria-Sensitized or Normal Mice at Different Times
After Infection
MEF monolayers were infected with 5-7 PFU of EMCV for 2 h and
then overlaid with 1 ml of MEM-2.

At the times noted, 1 ml

of MEM-2 or 1 ml of MEM-2 containing PC at a PC-to-MEF ratio
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of 20 was added to the existing media on the monolayers.
All cultures were harvested at 18 h and titrated for virus.
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mycobacteria-sensitized mice significantly inhibited EMCV
replication by 2 log^Q (99% inhibition) if they were added
at 2 or 4 h post-infection.

If the addition of PC was

delayed to 6 or 8 h post-infection, inhibition of replica
tion was still detected, but its magnitude had decreased to
1 log^Q (90% inhibition).

When PC were added as late as

12 h post-EMCV infection, no inhibition of viral replication
was apparent.

This data concurs with the results presented

in Figure 1 in that viral inhibition by PC from mycobacteriasensitized mice was not detected unless PC were in contact
with infected monolayers for a minimum of 10 h (addition of
PC at 8 h; harvest at 18 h).

Effect of PC from mycobacteria-sensitized mice on EMCV
replication in monolayers infected with high multiplicities
of virus.

To further study the inhibitory effect of PC

from mycobacteria-sensitized mice, 100% of the cells in the
monolayer were infected.

If viral replication was not in

hibited, this would indicate that reduction of viral titers
in monolayers infected with a low multiplicity of infection
(MOI) may in part be due to the inhibition of viral spread
to uninfected cells.

As observed in Table 9. PC from

mycobacteria-sensitized mice did not inhibit viral replica
tion when concentrations of virus sufficient to infect
every cell in the monolayer were used (MOI of 10 and 1).
In contrast, minimal inhibition occurred with a MOI of 0.5,

TABLE 9

Effect of PC from Mycobacteria-Sensitized Mice on

EMCV Replication in Monolayers Infected with High Multipli( 3.)

cities of Virus

Multiplicity
of
Infection

PC Source
Mycobacteria-

Normal

Inhibition
wone

Sensitized

(PFU/0.2

of EMCV
Replication

ml, log^Q)

log

(b)
10

10

6.4

6.5

6.7

none

1

6.5

6.5

6.5

none

0.5

6.2

6.7

6.7

0.5

0.00004

4.3

6.3

6.7

2.0

(5-7 PFU)
(a)

MEF monolayers that had been infected for 2 h with

different multiplicities of EMCV were washed and then incu
bated with media of PC from normal or mycobacteria-sensitized
mice at a PC-to-MEF r-::tio of 20.

Cultures v/ere harvested

18 h after infection and virus titers determined.
(b)

Inhibition of EMCV replication was determined by com

paring virus titers of cultures that had been infected with
similiar concentrations of EMCV and subsequently incubated
with PC from normal or mycobacteria-sensitized mice.
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and maximal inhibition (2 log^Q or 99%) was detected when
5-7 PFU (MOI of 0.00004) were used.

Inhibition of EMCV replication by PC from mycobacteriasensitized mice in the absence of cytotoxicity to monolayers*
To study in more detail the mechanism of viral inhibition
by PC, EMCV-infected and uninfected monolayers that had
been labeled with Na£^1CrO^ were incubated at a PC-to-MEF
ratio of 20, and the amount of ^Cr released into the super
natant fluids was determined.

The data in Table 10 indicate

that uninfected monolayers overlaid with PC from mycobacteriasensitized or normal mice or monolayers with media alone
released similiar amounts of -^Cr into the culture media
after 18 h of incubation.

Furthermore, when EMCV-infected

monolayers were incubated with PC from mycobacteria-sensitized mice, the amount of

51
J
Cr

released was similiar to

that detected in uninfected monolayers.

In contrast, 17%

and 21% more *^Cr was released from infected monolayers
incubated with PC from normal mice or media alone.

The

51
increase m ^ Cr release from these cultures correlated
with cytopathy consequent to viral replication; viral titers
were more than 2 log^Q greater than in cultures incubated
with PC from mycobacteria-sensitized mice.

In vitro inhibition of EMCV replication by PC from myco
bacteria-sensitized athymic nude mice.

Previous in vivo

work by Lodmell and Swalt (40) had shown that administration

TABLE 10

Inhibition of EMCV Replication by PC from Myco

bacteria-Sensitized Mice in the Absence of Cytotoxicity to
Monolayers

Treatment of Monolayers
PC Source

%

Virus

51Cr

Re

leased from
i
(a)
monolayers

Infection

Virus
I'iter^ K )
FFU/0.2 ml.
log10

MycobacteriaSensitized

-

44

none

Normal

-

41

none

None

-

44

none

Sensitized

+

40

3.8

Normal

+

57

6.0

None

+

61

6.2

Mycobacteria-

(a)

Na2~^CrO^ labeled uninfected and EMCV-infected (5-7 PFU)

MEF monolayers were incubated with media alone or PC from
normal or mycobacteria-sensitized mice at a PC-to-MEF ratio
of 20.

Eighteen hours later the percentage of -^Cr released

from the cells was determined.
(b)

EMCV replication was determined in separate unlabeled

MEF monolayers incubated for 18 h with PC from the same mice
that v/ere used for the ^Cr cytotoxicity assay.
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of the nonviable mycobacterial emulsion to neonatally
thymectomized C57BL/lOScN mice or athymic (nude) mice
protected these animals against a lethal challenge of EMCV.
Based on this data, it was suggested that the T lymphocyte
was unimportant in the in vivo mechanism of protection.
To study this observation .in vitro, PC from mycobacteriasensitized nude and euthymic mice were incubated on EMCVinfected MEF monolayers.

The data in Table 11 show that

viral replication was inhibited 2 log^g (99% inhibition)
with PC from mycobacteria-sensitized nude mice as compared
to 1.4 log^Q and 1.2 log^0, respectively, with PC from
mycobacteria-sensitized C57BL/lOScN mice and the BALB/c
haired littermates.

Inhibition of Ei-iCV replication with supernatant fluids
from PC cultures of mycobacteria-sensitized mice.
point

At this

the data indicated that an antiviral mediator

might be responsible for inhibition of viral replication
because a) marked inhibition (>90%) was not detected unless
PC were in contact with infected monolayers for 8-10 h
(Figures 1 & 2), b) cytotoxicity was not detected in
monolayers incubated with PC (Table 10), and c) PC did not
inhibit viral replication if every cell in the

monolayer

was infected before addition of the PC (Table 9).

To test

for an antiviral mediator, supernatant fluids were produced
by incubating PC from mycobacteria-sensitized and normal mice
for various intervals.

The data in Table 12 show that no

TABLE 11

Effect of PC from Mycobacteria-Sensitized Athymia;
(a)
Nude Mice on Inhibition of EMCV Replication

Source of PC

Strain of
Mouse Used

Mycobacteria-

Inhibition of

Normal

Sensitized

C573L/lOScN

EMCV
Replication

(PFU/0.2 ml, log1Q)

lo§l0

4.0

5.4

1.4

4.5

5.7

1.2

3«0

5*0

2.0

BALB/c haired
(nu/+)
Athymic Nude
(nu/nu)

(a)

MEF monolayers that had been infected with 5-7 PFU of

EMCV for 2 h were incubated at a PC-to-MEF ratio of 20 with
PC from normal or mycobacteria-sensitized C57BL/lOScN, and
BALB/c haired (nu/+) and athymic nude (nu/nu) mice.

Eighteen

hours later cultures were harvested and titrated for virus.
(b)

EMCV inhibition was determined by comparing virus titers

of cultures incubated with PC from mycobacteria-sensitized
and normal mice of the same strain.

Monolayers without PC

had a virus titer of 10^*^ PFU/0.2 ml, log^Q.
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activity was detected in 2 h fluids, whereas media harvested
at 4 h post-incubation had slight activity and media har
vested thereafter significantly inhibited EMCV replication
(>90% to >99%).

These results agree with the previous

kinetics data which indicated that an 8-10 h incubation
period of PC with infected monolayers was necessary before
significant viral inhibition was detected (Figures 1 & 2).
After u.v.-inactivation of infectious EMCV, antiviral activ
ity also was detected in supernatant fluids of cultures in
which EMCV-infected MEF monolayers were incubated with PC
from mycobacteria-sensitized mice (data not shown).
The antiviral supernatant fluids subsequently were
diluted and tested in an antiviral assay to determine
their concentrations.

The 24 h preparation from this ex

periment could be diluted 1:32 (data not shown); most active
supernatant fluids, however, could only be diluted ls8.
Supernatant fluids from PC of mycobacteria-sensitized athymic
(nude) mice also contained antiviral activity; in contrast,
PC from mice injected with TSO or normal mice did not
release a mediator.

Interestingly, active supernatant fluids

were never detected from PC of mycobacteria-sensitized mice
that failed to inhibit replication (data not shown).

Effect of serum and peritoneal washes from mycobacteriasensitized mice on EMCV replication.

Because a factor in

supernatant fluids appeared to be involved in the inhibition
of viral replication, attempts were made to detect antiviral

TABLE 12

Inhibition of EMCV Replication with Supernatant
(a)
Fluids from PC Cultures of Mycobacteria-Sensitized Mice

bated Before
Supernatant
Fluid Harvested

Inhibition

Source of PC

Hours PC Incu

Myco

Normal

of EMCV
Replication^^

bacteriaSensitized

logl0

(PFU/0.2 ml, l o g 1 0 )

(a)

2

6.8

6.8

none

4

6.3

6.8

0.5

8

4.7

6.5

1.8

12

4.8

6.8

2.0

18

5.0

6.6

1.6

24

4.7

6.8

2.1

Supernatant fluids were harvested from PC. of mycobacteria-

6
sensitized and normal mice that were cultured at 5 x 10
PC/ml.

This is the sane concentration of PC that is normally

incubated with infected monolayers.

Following harvest, the

fluids were centrifuged, mixed with an equal volume of MEM-2
and subsequently overlaid on MEF monolayers that had been
infected for 2 h with 5-7 PFU of EMCV.

Eighteen hours later,

the MEF cultures were harvested and titrated for virus.

Cul

tures incubated with MEM-2 alone had a titer of lO^*^ PFU/0.2
ml, log1Q.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers in cultures of mycobacteria-sensitized
57

and normal mice that were incubated with supernatant fluids
harvested at the same interval.
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activity from other fluids of mycobacteria-sensitized mice.
Serum from these mice diluted 1:5 in MEM as compared to
serum at the same dilution from normal uninfected mice
never inhibited viral replication (data not shown).

Be

cause mouse serum is toxic to monolayers higher concentra
tions could not be used in the assay.

Thus, in retrospect,

antiviral activity may have been present in the sera, but
it was too dilute to detect at the concentrations tested.
Peritoneal washes from mycobacteria-sensitized and
normal mice concentrated 10-to-20 fold were incubated with
EMCV-infected MSF monolayers in another attempt to detect
antiviral activity.

No inhibition of viral replication

was observed with these fluids (data not shown).

Effect of supernatant fluid antiviral activity on EMCV
titrations in ML cells.

In the previous in vitro experi

ments, entire cultures were harvested from EMCV-infected
MEF monolayers after 18 h of incubation.

Because PC sub

sequently were shown to release an antiviral factor (see
Table 12), it was considered that the mediator might possibly
be influencing the EMCV titration assays even though titrations were done at dilutions of

-3
10 J and supernatant

fluids usually were not active at dilutions

1:8.

Further

more, the mediator is inactive on the ML cells used for
EMCV titrations (data not shown).

Nonetheless, to be cer

tain the mediator was not an influence, an experiment was
designed in which entire cultures, washed monolayers only,

60
or supernatant fluids only were assayed.

The data in

Table 13 indicate that the mediator had no adverse effects
on EMCV titrations in ML cellst replication was inhibited
2»1 log10, 2.5 log10 and 2.2 log10 when entire cultures,
washed monolayers only or fluids only were assayed.

Continuous production of the antiviral mediator by PC
of mycobacteria-sensitized mice.

To determine the length

of time the mediator was produced in culture, supernatant
fluids were harvested after 24 h of incubation, the PC were
washed, and then refed with fresh media; washing and refeeding was repeated 5 times at 24 h intervals.

Without

refeeding, supernatant fluids inhibited viral replication
by 1.6 log^Q ( >90fo) \ interestingly, after one or two
refeedings, inhibition increased markedly to 3-3 (^99.9#)
and 2.6 log^Q ( >99%), respectively.

Antiviral activity

was still present but began to wane ( >90% inhibition)
during the third refeeding and was not detected after the
fourth of fifth (Table 14).

Effect on EivlCV replication of supernatant fluids from
PC cultures of mycobacteria-sensitized or normal mice incu
bated with various concentrations of FCS.

In an attempt

to increase the antiviral activity of supernatant fluids,
PC from mycobacteria-sensitized or normal mice were incubated
in different concentrations of FCS.

Increasing the amount

of FCS up to 20# (a ten-fold increase over the usual

TABLE 13

Effect of Supernatant Fluid Antiviral Activity on
EMCV Titrations in ML Cells^3^

Portion of

PC Source

MEF Culture

Myco-

Assayed

bacteria-

Normal

Inhibition
None

of EMCV
Replication^ ^

Sensitized

1°610

Entire Culture

4.5

6.6

6.7

2.1

MEF Cells only

3.6

6.1

6.2

2.5

4.0

6.2

6.5

2.2

Culture fluid
only

(a)

MEF monolayers that had been infected with 5-7 PFU of

EMCV for 2 h were incubated with PC from mycobacteria-sensi
tized or normal mice at a PC-to-MEF ratio of 20.

After 18 h

of incubation, entire cultures, washed monolayers only or
media only were harvested and titrated for EMCV.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers in the same portions of cultures incu
bated with PC of mycobacteria-sensitized or normal mice.
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TABLE 14

Continuous Production of the Antiviral Mediator "by
(a)
PC of Mycobacteria-Sensitized Mice

Source of PC

Number of Times
Culture !Refed

Myco-

at 24 h

bacteria-

Intervals

Inhibition

Normal

of EMCV

D 1 • + * (k)
Replication

Sensitized

loSl0

(PFU/0.2 ml, iogio)

4.8

6.4

1 .6

1

3.2

6.5

3.3

2

3.2

5.8

2.6

3
4

5.0

6.1

1.1

6.8

6.4

none

5

7.1

7.0

none

NONE

(a)

Supernatant fluids of PC cultures from mycobacteria-

sensitized or normal mice at 5 x 10° PC/ml were harvested
after 24 h of incubation and the PC then were washed and
refed with the same amount of fresh MEM-2 as was removed.
This process was repeated for 5 days.

All fluids, at a 1:2

dilution, were incubated on MEF monolayers that had been
infected with 5-7 t'FU of EwCV for 2 h.

Cultures were har

vested at 18 h and titrated for virus.
(b)

Inhibition of EMCV replication was determined by com

paring viral titers in cultures overlaid with supernatant
fluids.from PC of mycobacteria-sensitized and normal mice

62

after the same number of refeedings.

Monolayers incubated

without supernatant fluids had a viral titer of 10K"^ PFU/
0.2 ml, log^Q.
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concentration) did not improve the effectiveness of super
natant fluids to inhibit EMCV replication (Table 15)•

In

fact, after additional dilution to 1»10, only fluids from
PC incubated in 2$ FCS were positive (data not shown).

Hereafter, all supernatant fluids were harvested from PC
of mycobacteria-sensitized mice that were incubated in MEM-2.

Effect of concentrated supernatant fluids from PC
cultures of mycobacteria-sensitized and normal mice on
EMCV replication.

Supernatant fluids were concentrated

under vacuum pressure in another attempt to enhance their
antiviral activity.

The data in Table 16 indicate that

supernatant fluids concentrated 5-to-10 fold were more
effective than unconcentrated fluids in the inhibition of
EMCV replication.

When supernatant fluids from PC cultures

of mycobacteria-sensitized mice were concentrated 10-fold,
inhibition of EMCV replication increased 0.5 log^Q, from
1.7

L°§^O

unconcentrated fluids) to

2.2

log^Q.

Un

fortunately, at the same concentration in which supernatant
fluids showed increased antiviral activity,, they also
became toxic, in that MEF monolayers usually died before the
18 h assay was completed.

Because the increased activity

of the concentrated supernatant fluids may have been due
to toxicity, and the antiviral effects were only marginal,
this procedure was not continued.

TABLE 15

Effect on EMCV Replication of Supernatant Fluids

from PC Cultures of Mycobacteria-Sensitized or formal Mice
( 3.)

Incubated with Various Concentrations of FCS

Concentration
of FCS

Source of P,C
Myco

Inhibition

Normal

of EMCV
Replication^)

bacteriaSensitized

iog10

(PFU/0.2 ml, log10)

(a)

20#

5-5

6.4

0.9

10#

5.3

6.2

0.9

2#

5.3

6.2

0.9

PC at1 5 x 10^ PC/ml, from mycobacteria-sensitized and

normal mice, were incubated for 18 h in MEM with various
concentrations of FCS.

The fluids were diluted 1:2 in

MEM containing different concentrations of FCS so that the
final concentration of FCS in all media was 10#.

Monolayers

which had been infected for 2 h with 5-7 PFU of EMCV were
subsequently overlaid with the fluids and 18 h later, entire
cultures were harvested and titrated for EMCV.
(b)

Viral inhibition was determined by comparing the virus

titers incubated with supernatant fluids from PC cultures of
mycobacteria-sensitized and normal mice that had been grown
in the same concentration of FCS.

Cultures incubated without

supernatant fluids had a viral titer of 10^PFU/0.2 ml,

TABLE 16

Effects of Concentrated Supernatant Fluids from PC

Cultures of Mycobacteria-Sensitized and Normal Mice on EMCV
(a)
Replication

Concentration

PC Source

of Supernatant

Myco

Fluid

bacteria-

Inhibition

Normal

of EMCV
(b)
Replication

Sensitized
(PFU/0.2 ml, log^)

(a)

none

5.0

5X

5.1

10X

4.3

<

(log10)

6.7

1.7

7.0

1.9

6.5

2.2

Eighteen hour supernatant fluids of PC cultures from

mycobacteria-sensitized or normal mice were used unconcentrated or were concentrated in dialysis tubing under vacuum
pressure at 4°C before incubation on MEF monolayers that
had been infected with 5-7 PFU of EMCV for 2 h.

After 18 h

incubation, cultures were harvested and titrated for virus.
(b)

Inhibition of EMCV replication was determined by com

paring virus titers in cultures overlaid with similiarly
concentrated supernatant fluids from PC cultures of myco
bacteria-sensitized and normal mice.

Monolayers without

supernatant fluids had a titer of 106*7 PFU/0.2 ml, log1Q.
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6?
Effect on EMCV replication of supernatant fluids from
PC cultures of mycobacteria-sensitized or normal mice that
were stimulated with PPD or OT.

The mycobacterial antigens

PPD or OT were added to PC cultures from mycobacteriasensitized or normal mice or to media only and the super
natant fluids were harvested 18 h later.

The data in

Table 17 indicate that supernatant fluids from stimulated
PC cultures of mycobacteria-sensitized mice had enhanced
antiviral activity as compared to fluids harvested from
PC of the same mice that had not been stimulated.

Stimu

lated PC from mycobacteria-sensitized mice released media
tors which inhibited EMCV replication 1.5-1.7

a

1:2 dilution; these fluids were still active at a 1:128
dilution (data not shown).

In contrast, the same PC that

were not stimulated released mediators which inhibited
EMCV replication by only 0.6 log10 at a 1:2 dilution; this
activity could only be diluted to 1:8.

The addition of

PPD or OT to PC cultures of normal mice did not elicit
release of an antiviral mediator.

Similiarly, the antigens

alone had no effect on viral replication if they were in
cubated with the MEF used in the antiviral assay (Table 17).

Interferon activity in supernatant fluids from PC
cultures of mycobacteria-sensitized mice.

To determine

if the antiviral activity in supernatant fluids was inter
feron, active supernatant fluids were incubated on unin
fected MEF monolayers for 24 h, the monolayers were washed,

TABLE 17

Effect on EMCV Replication of Supernatant Fluids

from FC Cultures of Mycobacteria-Sensitized or Normal Mice
that were Stimulated with PPD or 0T^a^

Antigen

PC Source

Added to

Myco-

PC Culture

bacteria-

Normal

Inhibition
None

of EMCV
Replication^

Sensitized

(PFU/0.2 ml, log10)

50 ug OT
100 ug PPD
none

(a)

50

u§

5.5
4.8
5*8

(logi0)

7.0

7.0

6.5

6.3

1.5
1.7

6.4

6.5

0.6

°f OT or 100 ug of PPD wore added to i;C cultures

of mycobacteria-sensitized or normal mice at 5 x 106 PC/ml
or to media alone.

After an 18 h incubation the supernatant

fluids were harvested and tested on MEF monolayers which
had been infected with 5-7 PPU of EMCV for 2 h.

Viral titers

were determined 18 h later.
(b)

Inhibition of viral replication was determined by com

paring viral titers in cultures overlaid with supernatant
fluids from PC cultures of mycobacteria-sensitized or normal
mice incubated with similiar amounts of PPD or OT.
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challenged with VSV or EMCV and plaques counted; if plaque
formation was inhibited > 50%, interferon was present.
The data in Table 18 indicate that an interferon-like
mediator was present in the supernatant fluids from PC
cultures of mycobacteria-sensitized mice.

Further char

acterization of the mediator (Table 18) suggests that the
interferon differed from both type I and type II mouse
interferonsi it was labile to both pH 2 for 24 h at 4°G and
heat at 56°C for 30 min, yet inhibited EMCV, VSV, HSV and
VV replication) was nondialyzable, sensitive to trypsin
(1.25 mg/ml) for 5 h at 37°C»and did not sediment after
centrifugation at 100,000 x g for 1 h.

In addition, it

resembled a type II interferon because neither type II
interferon nor the supernatant fluid interferon inhibited
viral replication in GPK cells, whereas, type I interferon
was active in these monolayers.

Additional characterization

of the interferon in supernatant fluids of PC cultures
from mycobacteria-sensitized mice was done by incubating it
with uninfected monolayers for various lengths of time
and then challenging the monolayers with EMCV.

The results

in Table 19 indicate that when similiar units of interferon
were tested, type I interferon protected monolayers when
added 2 h prior to viral challenge, the type II interferon
required 8 h, and the PC supernatant interferon 18 h.
Because of these differences additional tests were done
tb determine if the mediator in supernatant fluids was
interferon and not virucidal or possibly anti-EMCV antibody.

TABLE 18

Identification of the Antiviral Factor as Inter

feron in Supernatant Fluids from PC Cultures of Mycobacteria(3.)
Sensitized Mice

Treatment

Type I
Interferon

Type II
Interferon

Unstimulated
PC Interferon

Stable at pH 2 for 24 h
at 4°C

+

Stable at 56°C for 30 min

-

+

Nondialyzable against PBS
o
for 24 h at 4 C

+

•+•

Stable to trypsin for 5 h
o
at 37 C

1

—

Sediments at 100,000 x g
for 1 h
Additional Characteristics
+

Inhibits EMCV or VSV in MEF

+

Inhibits RNA and DNA Viruses

+

Active in GPK cells

+

+

+
+

+

O

18

Minimum time (h) needed to
inhibit virus in uninfected
monolayers

2

Neutralized viruses
Neutralized by anti-type I
mouse interferon

+

Neutralized by anti-type II
+

mouse interferon
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+ = yes
- = no

(a)

All assays were performed with 2-6 units of interferon.

The type I interferon was prepared by harvesting sera from mice
2 h post-injection of 50 ug of poly (I)-poly (C); the type II
interferon was prepared in mycobacteria-sensitized mice that
were challenged i.v. with OT (see Materials and Methods).
The unstimulated PC interferon was present in supernatant
fluids from 18 h cultures of PC from mycobacteria-sensitized
mice.
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TABLE 19

Time Necessary to Detect Interferon Activity in Un-

(cl)
infected MEF Monolayers with Antiviral Substances

Intervals (h) Antiviral
Substance Incubated with
MEF Monolayers Before

Antiviral Substances
Type I
Interferon

Viral Challenge

(a)

Type II
Interferon

Unstimulated
PC Interferon

(# of Plaques)

0

29,27

30,26

15,27

1

22,19

27,28

18,21

2

11,9 *

19,13

15,27

4

23,16

21,24

6

6,9 *
(b)
ND'

ND

18,18

8

5.4- *

5,6 »

24,18

10

ND

ND

21,30

12

2,2 *

4,2 *

15,21

18

ND

ND

3,6 *

20

ND

ND

0,6 *

24

1,1 *

0,1 *

0,3 *

0.5 nil of each preparation diluted in

MEiVI-2

to contain

2 units of interferon was added to duplicate monolayers and
at the times noted, the monolayers were washed and challenged
with 20-30 PFU of EMCV.

24 h later, the number of plaques

was reduced by > 50$ (#) from the number of plaques that were
present in the virus control wells (0 h).
(b) Not done
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The data in Table 20 indicate that the mediator present
in active supernatant fluids did not neutralize or inac
tivate EMCV even though the amount of time for the neutrali
zation test was extended to cover the full length of the
usual inhibition assay.

The decreased plaque counts de

tected at 18 and 24 h were probably due to the lability of
EMCV because similiar decreases were noted when EMCV was
incubated in media alone or with supernatant fluids pre
pared from PC of mycobacteria-sensitized or normal mice.
Additional experiments also determined that active super
natant fluids did not interfere with EMCV adsorption and
subsequent infection of MEF monolayers (data not shown).
Thus, it was concluded that an interferon was present in
supernatant fluids prepared from PC of mycobacteria-sensi
tized mice.

At. this time the interferon did not appear

to be type I, but it was somewhat similiar although not
identical to type II interferon.
The differences between the type II interferon pro
duced by unstimulated PC of mycobacteria-sensitized mice
in this investigation and known classical type II interferons
detected by others (44, 50, 53)» may tie due to the lack of
stimulation of the PC by specific antigens; classical type
II interferon is, by definition, produced by sensitized
cells after specific antigenic restimulation (16, 18, 77).
To determine if this was so, supernatant fluids were pre
pared from PC cultures of mycobacteria-sensitized mice that,
had been incubated with and without PPD.

The supernatant

TABLE 20

Neutralization Test Using Supernatant Fluids from

(a)
PC Cultures of Mycobacteria-Sensitized and Normal Mice

Time of

Source of Supernatant Fluid

Incubation
(hours)

Mycobacteria-

Normal PC

Sensitized PC

None
(MEM-2)

(# of plaques)

(a)

1

32,28

31,27

33,25

2

23,26

22,31

26,24

4

23,27

32,23

36,33

8

15,22

16,16

16,18

12

21,20

17,17

25,26

18

15,10

8,14

13,12

24

4,5

2,1

1,4

0.3 m1 of the supernatant fluids or MEM-2 was incubated

with 0.3 ml of EMCV (approximately 35 PFU) for varying inter
vals at 37°C,

Samples were then assayed for the ability of

EMCV to form plaques on ML monolayers overlaid with nethocellulose.

The active supernatant fluid from PC of mycobac

teria-sensitized mice inhibited EMCV replication by > 1 log^Q
in MEF monolayers in a standard antiviral assay.
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fluids then were heated at 56°C for 30 min and assayed for
interferon activity.

It was determined that the interferons

were similiar in that both were labile to heat, and were,
in contrast, unlike the classical type II interferon control
which was stable after similiar treatment (data not shown).
Thus, it appeared that the differences between interferon
in supernatant fluids and standard type II interferon were
not attributed to the lack of antigenic stimulation in
PC cultures from mycobacteria-sensitized mice.

Anti-interferon assays.

The data presented to date

has alluded to the presence of a mediator similiar to type II
interferon in supernatant fluids from PC cultures of mycobacteria-sensitized mice.

To confirm the identity of this

mediator neutralization assays were done with an active
supernatant fluid and rabbit anti-type I and anti-type II
mouse interferons.

The data in Table 21 indicate that

anti-type II interferon, and not anti-type I interferon,
neutralized the antiviral activity present in supernatant
fluids from PC cultures of mycobacteria-sensitized mice.
Additional proof of this identification was shown by the
data which indicated that the two anti-interferons did
not cross react with the known type I and type II interferon
controls.

Thus a heat labile type II interferon was released

by PC from mycobacteria-sensitized mice.
did not

Furthermore, it

require antigenic stimulation for production but
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required twice

as

much time to protect uninfected

i.ifiF

monolayers from viral challenge as classical type II
interferon.

TABLE 2.1

Effect of Antibody to House Type I and Type II In

terferons on Antiviral Activity of Supernatant Fluids from
(a)
PC Cultures of Mycobacteria-Sensitized Mice

Experimental Groups

Plaque Counts
(Average of "3 monolayers)

Type I interferon + NRG^)

0

Type I interferon + anti-type I

15

Type I interferon + anti-type II

0

Type II interferon + NRG

3

Type II interferon + anti-type I

2

Type II interferon + anti-type II

13

Unstimulated PC interferon + NRG

5

Unstimulated PC interferon + anti-type I

3

Unstimulated PC interferon + anti-type II

12

Controls
Anti-type I + MEM-2

15

Anti-type II + MEM-2

17

NRG + MEM-2

16

(a)

Similiar units of antiviral activity were assayed against

rabbit anti-type I and anti-type II mouse interferons (see
Materials and Methods).

A 50# reduction in plaques as com

pared to control plaques constitutes interferon activity.
(b)

Normal rabbit globulin
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DISCUSSION
These studies have shown that PC from C$7BL/l0ScN.
mice sensitized with nonviable mycobacteria in an oil drop
let emulsion inhibit EMCV replication in MEF monolayers
when used at a PC-to-MEF ratio of 20.

PC from mice sensi

tized i.p. or i.v. 2-6 weeks previously with 50-500 ug
of M. tuberculosis were the most effective.

A series of

subsequent experiments indicated that CFW/R MEF monolayers
incubated with PC at 37°C for 18 h with low multiplicities
(5-7 PFU) of EMCV resulted in optimal inhibition of viral

replication.
The possibility that adverse tissue culture conditions
may have affected EMCV replication also was investigated.
It was determined that the pH of EMCV-infected cultures
incubated with media alone or PC from mycobacteria-sensi
tized or normal mice was not significantly different (pH
7.2-7.4) even though viral titers in cultures incubated
with PC from mycobacteria-sensitized mice were 2.2 log^Q
less than cultures incubated with PC from normal mice.
Furthermore, the addition of fresh media to EMCV-infected
cultures incubated with PC from mycobacteria-sensitized
mice did not markedly change the degree of viral inhibition.
These data excluded the possibility that unfavorable culture
conditions were responsible for the viral inhibition.
The kinetic studies indicated that PC from mycobacteriasensitized mice had to be in contact with the infected MEF
monolayers for 8-10 h to inhibit EMCV replication.
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to this time, EMCV replication was not affected.

Because

EMCV requires 6-8 h to replicate (17), it appeared that
viral replication was altered after the first and subsequent
cycles of viral growth.

This data supports the previous

hypothesis of Lodmell and Ewalt that viral replication was
necessary before inhibition of replication could be demon
strated (39).

In addition, studies using a high MOI in

dicated that inhibition of viral replication only occurred
when small amounts of virus were used to infect the mono
layers; if 100# of the monolayer cells were infected, no
inhibition of replication was observed.

Thus, PC from myco

bacteria-sensitized mice appeared to be inhibiting the
spread of EMCV to uninfected MEF cells which concurs with
the previously mentioned hypothesis.

Furthermore, studies

with radiolabeled MEF cells indicated that this inhibition
of viral spread by the PC was not due to cytotoxicity.
Because a) an 8-10 h incubation period was necessary
before viral

inhibition could be detected, b) decreased

EMCV titers were due to the inhibition of viral spread to
uninfected cells and c) cytotoxicity of MEF monolayers was
not detected, subsequent studies turned to the possibility
that an antiviral mediator produced by the PC
sible for viral inhibition.

was respon

It was determined that cell-

free supernatant fluids harvested from PC cultures of myco
bacteria-sensitized mice inhibited viral replication.
Supernatant fluids harvested from PC cultures 2 h after
incubation were inactive whereas those harvested at 4 h
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showed slight activity.

Similiar fluids harvested 8-24 h

after incubation markedly inhibited EMCV replication.
This data correlated well with the previously mentioned PC
kinetics data.

By stimulating the PC in culture with myco

bacterial antigens or concentrating the fluids under vacuum
pressure, the antiviral activity of supernatant fluids could
be enhanced.

Furthermore, when supernatant fluids were

removed from PC cultures of mycobacteria-sensitized mice
and the cells were refed with fresh media at 24 h intervals,
the PC were shown to produce the mediator for at least
72 h.

This result, in addition to the data which indicated

that neither nonviable cells nor the media in which the
PC were rendered nonviable inhibited viral replication,
indicated that the mediator was continually being produced
and was not preformed.

Serum or peritoneal washes from

mycobacteria-sensitized mice, however, did not contain
detectable antiviral activity.

Characterization of the

antiviral mediator(s) in supernatant fluids from PC cultures
of mycobacteria-sensitized mice indicated that an interferon
was responsible for the inhibition of EMCV replication.
This mediator was labile to trypsin, pH 2 for 24 h, and
56°C for 30 min.

In addition, it was nondialyzable, non-

cytotoxic to EMCV-infected MEF target cells, species, but
not viral specific, was not virucidal and did not neutralize
EMCV.

Furthermore, a rabbit anti-type II mouse interferon

neutralized its antiviral activity as well as the activity
of two known type II interferons.

In contrast, a rabbit

Si
anti-type I mouse interferon had no effect on the antiviral
activity of supernatant fluids.

Thus, a type II interferon

appeared to be responsible for the inhibition of EMCV
replication in MEF monolayers overlaid with FC or super
natant fluids from PC of mycobacteria-sensitized mice.
The type II interferon produced by PC from mycobacteriasensitized mice differed in several ways from classical
type II mouse interferon.

First of all, antigenic stimu

lation of the sensitized cells was not necessary for its
production even though similiar treatment did enhance the
titer.

By definition type II or immune interferon is pro

duced by previously sensitized cells after the cells are
stimulated by the antigens that were used for sensitization

(13).

However, there are a few reports in the literature

which indicate that type II interferon can be released
from cells without additional stimulation of the sensitized
effector cells (21 , 37, 53)•

In one such study, I\'euman and

Sorg demonstrated immune interferon production by macrophages
from spleen cell cultures of BCG-infected mice.

In this

study, the mice were reinfected with BCG prior to harvest
of their spleens (53)-

In the present investigation, how

ever, the mice were sensitized with nonviable mycobacteria
and never rechallenged prior to harvest of PC.

Morahan

et al. also have shown that adherent PC from mice injected
with Corynebacterium parvum or Corynebacterium acnes in
hibited replication of several viruses in vitro without
restimulation with corynebacterial antigens (37).

Interferon
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was postulated by these authors to be the mode of inhibition,
but definite proof was not cited.

In addition, Hirt et al.

reported the production of immune interferon by unstimulated
spleen cells from C. parvum-sensitized mice and in some
cases, from normal spleen cells after prolonged incubation (26).
In the system described herein, immune interferon
was produced in the apparent absence of antigenic stimu
lation; yet mycobacterial antigens could have been present
in phagocytic cells within the PC population.

Studies

conducted to determine the effector cell(s) in this system,
however, have shown that the cell is adherent but does not
phagocytize carbonyl iron, and PC depleted of esterase
positive and phagocytic cells produce an antiviral mediator
(Cent, et al., manuscript in preparation). In addition, PC from
i.v. injected mice inhibit EMCV replication and produced immune
interferon and attempts to visualize mycobacteria in the PC
by conventional staining techniques were unsuccessful (data
not shown).

Therefore, immune interferon apparently is

released from mycobacteria-sensitized PC without additional
stimulation.
Another characteristic of the type II interferon re
leased from PC of mycobacteria-sensitized mice that was
different from classical type II interferons was its lability
to heat at 56°C for 30 min; standard type II interferon is
identified as being heat stable for M h at 56°C (63).
Because the type II interferon identified in these studies
was produced without mycobacterial stimulation of sensitized
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cells, it may have been that a different type II interferon
was synthesized which could therefore account for its heat
lability.

However, when the type II interferon was produced

with PPD or 01 stimulation, the heat lability was the same
as the interferon that was present in unstimulated cultures.
Interestingly, there is a report in the literature of a
heat labile immune interferon (71).

Virelizier et al. de

tected such a mediator in mixed lymphocyte cultures which
decreased in titer from 450 to 54 units after 20 min incu
bation at 56°C (71).

This mediator was identified as type II

interferon because of its acid lability and antiviral
behavior.

The immune interferon detected in supernatant

fluids from PC cultures of mycobacteria-sensitized mice
also was different from standard type II interferon in the
amount of time that was necessary for similiar units of
interferon to be in contact with uninfected monolayers to
protect them from viral challenge; type I interferon re
quired 2 h, classical type II interferon 8 h, and the super
natant fluid mediator needed 18 h.

In addition, the ML

cell line originally used in these studies could not be
protected by the type II interferon present in supernatant
fluids whereas type I interferons were effective (data not
shown).

Consequently, it initially was thought that the

mechanism of viral inhibition was not due to interferon.
However, subsequent studies showed that classical type II
interferon did not protect these cells as well as ML cells
that were obtained for comparative studies.

It could only
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be concluded that the initial ML cells were somehow differ
ent from other ML cells, and they were no longer used in
subsequent interferon assays.

It would be interesting to

determine what is different about these ML cells that makes
them refractory to type II interferon.

This information

could possibly lend insight into how interferon protects
cells.

In addition, the different ML cells might be used

to differentiate between type I and type II interferons.
Interferons are considered to be heterogeneous mole
cules and this variability could account for the differences
between classical type II interferon and the interferon
found in PC cultures from mycobacteria-sensitized mice (18).
Molecular weights have been reported from 45,000 to 80,000
for type II interferon (77).

T-he heterogenicity of inter

feron molecules has been studied by Maehara and co-workers
in which differences in interferons were detected based
on the cellular source and mode of induction (44).

Recently

Stewart ^t al. have described two distinct type I interferons
(67), and. it would seem reasonable, therefore, that two or
more type II interferons also exist.

In fact, Youngner has

proposed that interferons can be as heterogeneous as anti
bodies even though they commonly are protein molecules which
require host synthesis to inhibit DNA and RNA virus replica
tion without neutralization of viral particles (77).
The in vitro production of immune interferon in this
study can be used to explain the previous in vivo protection
results reported by Lodmell and Ewalt (39. 40).

It was
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determined that mice which were sensitized i.v. or i.p.
with mycobacteria were resistant to i.p., i.v., i.m. and
s.c. EMCV challenge, results which would suggest that a
mediator was involved in protection (39).

Virus was de

tected in target organs 24 h earlier in unsensitized mice
than mycobacteria-sensitized mice (39), but EMGY did repli
cate in mycobacteria-sensitized mice because viremia was
detected at 72 h post-challenge in mice that subsequently
survived (40).

EMCV, however, failed to infect the CHS

which ultimately results in death (39).

Therefore, inter

feron which is able to protect uninfected cells as well as
slow cell division and concurrently slow viral replication
(23) could control an EMCV infection which usually would
overwhelm the immune system.

In addition, interferon is

known to cause changes in cell membrane surfaces (13. 46)
and this could alter the ability of EMCV to infect certain
cells including those of the CNS.

Whether immune interferon

regulates other parameters of the immune response _in vivo
in this system is still unclear.
Interferons have many effects on the immune system
as well as being antiviral mediators (77).

Type I interferon

has been shown to enhance specialized cell function (23)
especially associated with the T cell (13); these include
decreased cell division, synthesis of prostaglandins and
RNA

T cell

methylase and abolishment of delayed hypersensitivity

(DTH) reactions (13> 23).

Immune type II interferon, on the

other hand, has recently been postulated to be a major
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mediator of cellular immunity (71).

Sonnenfeld et al. have

described immune interferon to be 100 to 1000 times more
effective as an antiviral or regulatory molecule than type
I interferon.

In addition, type II interferon can be either

immunosuppressive or immunopotentiative depending on the
dose and time of application of interferon in relation to
antigen (Sonnenfeld, Mandel, and Merigan, personal communi
cation, 77).

Thus, it was concluded that the biological

roles of type II interferon may be both immunoregulatory and
antiviral (77).
Type II interferon was first detected by vVheelock in
1965 (72) and was described as immune interferon by Falcoff
(16).

Many studies have been conducted since that time

to examine its role in cellular immunity, however, the pre
cise mechanisms by which type II interferon functions within
the immune system are still relatively unknown (71).
Virelizier found that type II interferon protected glassadherent PC cultures from influenza virus and a highly
virulent strain of mouse hepatitis virus which normally
replicate in macrophages (71).

Macrophages also have been

associated with type I interferon by Manijias et al. in that
their phagocytic ability was enhanced by its presence (45).
A similiar situation was described by Huang e_t al. who
showed an increased phagocytosis of colloidal carbon particles
by mononuclear cells that had been pretreated with type I
interferon (27).

It would appear, therefore, that type II

interferon also might effect macrophage function in a
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similiar manner.

Nonetheless, Lodmell has shown that EMCV

was not adsorbed by cells in the plastic adherent cell
populations of PC from mycobacteria-sensitized mice (Pusateri,
et al..manuscript accepted for publication). In addition, pre
vious in vivo work has demonstrated that rapid elimination
of infectious EMCV by phagocytic cells from the sera of
normal or mycobacteria-sensitized animals did not differ
from 1-120 min after i.v. EMCV challenge (40).

Thus, it

would appear that enhanced phagocytosis as a result of
interferon activity can be eliminated as a possible mechanism
for the inhibition of EftCV replication in the in vitro and
in vivo studies.
I
In several instances, interferon has been associated
with the enhanced cellular cytotoxicity of viral-infected
and tumor cells by T cells, NK cells and K cells (14, 37, 60,
62).

In a study by Lindahl et al. it was demonstrated that

pre-treatment of sensitized lymphocytes for 6 h with
interferon significantly enhanced their cytotoxic activity
against allogenic tumor target cells (37).

This enhancement

was dose dependent and purified preparations of interferon
were more effective than crude preparations (37).

Similiarly,

Djeu ejt al. noted that i.p. injected interferon or interferon
inducers such as poly (I)-poly (C) could augment splenic iNK
cell activity against leukemia target cells.

This increase

in cytotoxicity also could be demonstrated in normal spleen
cell cultures after incubation for 18 h with interferon
inducers; anti-interferon destroyed the enhanced cytotoxicity
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both in vivo and in vitro (14).

Santoli also noted increased

NK cell activity against influenza-infected cells 6-24 h
after treatment of the effector cells with interferon (60).
In the majority of these studies, type I interferon was
used, but again, there is no reason not to speculate that
type II interferon could be operative in a similiar capacity.
For example, Simon et al. detected two killer cell helper
factors (KHF) in con A stimulated spleen cultures which
enhanced killer (K) cell activity (62).

One factor was

closely associated with, or identical to, immune interferon
in that the factor(s) could not be disassociated by pH
sensitivity or molecular weight separation techniques and
appeared to enhance the cytotoxicity of K cells by mechanisms
independent of the second factor (62).

Nonetheless, cyto

toxicity experiments done in this investigation with PC
from mycobacteria-sensitized mice indicated that neither
the PC nor the antiviral supernatant fluids were cytotoxic,
to EMCV-infected or uninfected MEF target cells.

An in

creased amount of -^Cr was released from monolayers incubated
with PC from normal mice or media alone, but this increase
was associated with cytopathy consequent to increased viral
replication.

Thus, cytotoxicity associated with enhanced

NK cell, T cell or K cell activity by immune interferon
does not appear to be a mechanism of inhibition by PC from
mycobacteria-sensitized mice.

Additional evidence which

indicated that the NK cell was not important in the inhibition
of EMCV replication has been shown by Wolfe et al. (74) who

demonstrated that the NK cell was labile after incubation
at 37°C for 8 h.

Temperature experiments in this investi

gation with PC from mycobacteria-sensitized mice had shown
that the greatest inhibition of viral replication was de
tected at 37°C.

Furthermore, the kinetic studies indicated

that no significant inhibition of virus replication by PC
occurred before 8 h of incubation.

Killer (K) cells, which

require specific antibody to function (41), also can be
discounted in this system because previous in vivo work
indicated that 50% of the mycobacteria-sensitized mice which,
survived EMCV challenge did not have serum EMCV Ab (39).
In addition, in vitro data indicated that supernatant
fluids from PC cultures of mycobacteria-sensitized mice
did not neutralize EMCV.
Mechanisms for inhibition of viral replication also
did not appear to involve the functionally mature T lympho
cyte.

PC at a PC-to-MEF ratio of 20 from athymic nude mice

sensitized with mycobacteria inhibited EMCV replication
in vitro more effectively than PC from their similiarly
sensitized nu/+ euthymic littermates or C57BL/l0ScN mice.
In addition,

PC

from sensitized nude mice, but not the

euthymic mice, inhibited EMCV replication at PC-to-MEF ratios
2 and 1 (Lodmell et. al., manuscript accepted for publication).
Recently, however, Wietzerbin et al. have reported that
athymic nude spleen cells stimulated with phytohemagglutinin
(FHA) did produce immune interferon

(73).

A

minor theta-

bearing cell population appeared to be the effector cell
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although co-operation with other cells was required for the
interferon production (73)-

Nonetheless, studies with PC

from mycobacteria-sensitized mice have shown that the ef
fector cells adhered to nylon wool columns which is further
evidence against T cell involvement(Cent jet al. ,manuscript in
preparation). This data brings up an interesting,; point in that
many investigators have stated that sensitized T cells were
primarily responsible for production of classical immune
interferon (13» 53» 73)-

Perhaps the variable properties

of the immune interferon detected in these studies can be
explained because it was produced by cell populations in
dependent of the T cell.
Additional mediators of cellular immunity that have
been detected in other studies could be partially responsible
for EMCV inhibition because they have been closely associated
with or unseparable from immune interferon (4, 50, 62, 75)•
One study was described by Youngner et al. in which similiarities in antigenic, biological and physical properties
were noted between migration inhibitory factor (MIF) and
immune interferon in sera of BCG-infected mice rechallenged
with OT or live BCG (75)•

For example, maximum production

of the two mediators occurred at 2-3 weeks after infection
in BCG-sensitized mice and inoculation of specific antigen
that resulted in delayed hypersensitivity reactions.

The

peak activities of the two molecules corresponded to a
molecular weight of 45,000 to 80,000 and both substances
were sensitive to pH 2 (75)-

In subsequent studies, Youngner
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showed that immune interferon and the high titered MIF
activity were produced by a heterogeneous cell population
of T and B lymphocytes, whereas type I interferon with low
titered MIF activity was produced by separate cell popula
tions (76).

Differentiation of the properties of MIF and

immune interferon proved difficult and still has not been
resolved (76).

More recently, antiviral mediators have

been detected from nonstimulated tissue culture cells in
cluding secondary MEF cells (4, 28).

These cell-produced

viral inhibitors (CVI) were neither viral nor species
specific, were sensitive to trypsin and appeared to inhibit
viral attachment and penetration into the target cells.
It is possible that the in vitro inhibition of viral repli
cation in MEF monolayers in the studies reported herein
may have been in part due to CVI.
Even though interferons have been shown to have varied
effects on the immune system, their antiviral effects are
beyond reproach; on a molar basis, interferons are some of
the most potent biological molecules known (18).

Several

investigators over the course of many years have tried to
resolve the means by which they protect cells against
viral infection (18).

There are various mechanisms that

have been proposed and the results appear to differ depending
on the viral system that is studied (48).

Many substances

can induce interferon synthesis and some of the most
effective are double-stranded RNA's; they are so
effective that some investigators have proposed that all
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inducers work by causing the production of double-stranded
RNA (46).

Regardless of the mode of induction, it is fairly

well established that derepression of the interferon gene
is the event that initiates interferon production.

The in

terferon molecules then diffuse to neighboring cells and bind
to their surfaces; this binding initiates the synthesis of at.
least three cellular proteins (46).

The proteins are in

active until the cells in which they are produced are in
fected with a virus or exposed to double-stranded RNA.

This

requirement for activation protects cellular metabolism from
the inhibitory effects of the proteins.

The first of these

molecules is a protein kinase, which in the presence of
double-stranded RNA and ATP,1 transfers a phosphate group to
an initiating factor needed for viral protein synthesis.
This phosphorylation inactivates the viral initiation factor
and thus, blocks viral protein synthesis.

The second cellular

protein catalyzes the formation of a nuclease activator from
ATP which then activates the third cellular protein, an endonuclease which breaks down viral mRNA molecules before they
can direct synthesis of viral protein (46).

There has been

contradicting evidence on whether viral mRNA is more sensi
tive to the actions of interferon than cellular RNA and the
issue still has not been resolved.

Nonetheless, there are

at least two pathways by which viral inactivation can occur
as a result of interferon production; one is at the initia
tion of viral protein synthesis and the other at mRNA
translation.

Interferon also has been shown, by a different
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mechanism, to affect the ability of some RNA tumor viruses
to spread to uninfected cells.

The synthesis of these

viruses is not affected by the three cellular proteins
described previously because the RNA viral genome is trans
lated into DNA, incorporated into the cellular DNA and
replicated along with the cellular genome.

Friedman has

found, however, that the virions are impaired from budding
out of infected cells and has speculated that cellular
membrane changes, caused by interferon pre-treatment, in
hibited viral spread (46).

These changes in the interferon-

treated cellular membrane have not been well characterized.
In the model system of nonspecific immunity reported
herein, the production of immune type II interferon has
been detected in PC cultures from mycobacteria-sensitized
mice and it is proposed that this antiviral molecule was
responsible for the inhibition of EMCV replication.

Al

though antigenic stimulation of the PC was not necessary
for the release of interferon, the addition of mycobacterial
antigens such as PPD or OT enhanced its titer.

This anti

viral molecule did not appear to be preformed because non
viable PC were ineffective.

In addition, an 8-10 h incuba

tion period was necessary to detect viral inhibition with
FC from mycobacteria-sensitized mice on infected MEF and a
similiar amount of time was necessary for PC cultures to
release sufficient concentrations of interferon to signifi
cantly inhibit EMCV replication.

Several differences were

noted between the immune interferon detected in these studies
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and classical type II interferon.

Included were heat labil

ity and the requirement that over twice the amount of time
was needed to protect uninfected monolayers against viral
challenge with similiar units of interferon (18 h vs. 8 h
for standard type II interferon).

However, there were many

similiarities between these two antiviral substances in that
both acted by inhibiting viral spread to uninfected monolayer
cells, and they were neither cytotoxic nor able to neutralize
EMCV.

In addition, both molecules were acid labile, trypsin-

sensitive (an indication that the active portion of the
molecules was protein), and both inhibited the replication
of several RNA and DNA viruses, but only in mouse cells.
Lastly, the interferon present in supernatant fluids from
PC cultures of mycobacteria-sensitized mice as well as
standard type II interferons were neutralized by rabbit
anti-mouse type II interferon.

Further studies with this

system of nonspecific immunity could include 1) a more
detailed biochemical analysis of the differences between
classical immune interferon and the type II interferon de
tected in supernatant fluids, 2) a thorough study of the
difference(s) in the ML cells initially used in this study
which rendered them insensitive to type II interferon treat
ment and 3) the regulation of the immune response _in vivo
that is a result of type II interferon production.
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